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Chapter I 
INTRODUCTION 

INTRODUCTION 
Hypertension occurs in about 15 to 20% of the adult population 
in developed countries (1). The accompanying high rate of mor-
bidity and mortality (2) can be reduced by lowering the blood 
pressure with medical treatment (3,4). Until now prevention of 
hypertension has not met with great success. Relaxing therapy 
(5), dietary measures for weight reduction (6) and salt res-
triction (7) are of only limited value. Definitive cure of 
hypertension by surgical intervention is possible in only a 
small proportion of the hypertensive population. It seems 
attractive to aim at a reduction of the total peripheral vas-
cular resistance, since an elevation of this variable is the 
main haemodynamic abnormality in most types of established 
hypertension (8). The mechanisms by which the vascular resistance 
increases, are still unclear. Borst and Borst-de Geus (9) and 
Guyton et al. (10) have proposed that the primary defect in 
hypertension is a decreased ability to excrete salt. This leads 
to an increase of blood volume with a consequent rise in car-
diac output. Vascular autoregulation is then responsible for the 
rise in peripheral resistance. Folkow (11) has stressed the 
importance of secondary structural vascular changes for the 
increase of total peripheral resistance in established hyper-
tension. Other theories include an overactivity of pressor 
substances such as catecholamines (12), vasopressin (13), 
angiotensin-II (14), corticosteroids (15), sodium (16), excess 
stimulation of the sympathetic nervous system (17), or an 
abnormal response to pressor mechanisms (16). Theoretically even 
a deficiency of vasodilator substances such as "renomedullin" 
(18), prostaglandins, kinins (19), etc. could play an important 
role. Lever has summarized this confusion as follows: "It is 
a contentious field, partly because there are so many ideas on 
pathogenesis and partly because some of them are presented as 
mutually exclusive or rival options" (20). 
Hypertension in renal disease seemed to be an exception to the 
rule, since in this condition a high cardiac output can be 
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present accompanied by a normal or only slightly elevated 
total peripheral resistance. However, Neff et al. (21) have 
demonstrated that, after correction of the anaemia, which is 
generally present in these patients, cardiac output returns to 
normal levels, whereas the peripheral resistance increases to 
abnormally high levels and blood pressure remains high. This 
suggests that there is also overactivity of a vasoconstricting 
mechanism in patients with a renal hypertension. It is obvious, 
that in renal disease salt retention and overhydration are 
additional complicating factors. This is supported by the 
observation that in most hypertensive patients with end-stage 
renal failure blood pressure returns to normal levels after 
sufficient salt and water have been removed during haemodialysis 
(22). However, other changes occurring during haemodialysis may 
be important for this reduction of blood pressure. In a small 
proportion of patients on chronic intermittent haemodialysis 
blood pressure remains high despite vigorous ultrafiltration. 
In most of these patients this problem can be resolved by 
bilateral nephrectomy (22) . This suggests the production of a 
vasopressor agent by the kidney. Renin seems the most likely 
candidate. Therefore we have studied the renin-angiotensin 
system in patients on haemodialysis. It appeared that an in-
appropriate stimulation of this system in relation to the 
sodium-volume state played a major role in sustaining hyper-
tension in these patients. A comparable but less dominant, 
abnormal interrelationship between these two factors has 
been established in patients with renal (23) or essential 
hypertension (24). Obviously, these findings do not preclude 
the role of other vasoconstricting factors in hypertension. 
In the treatment of hypertension, diuretic and beta-adreno-
ceptor blocking agents, either alone or in combination, are 
most commonly used because of their favourable therapeutic 
effect with a relatively low incidence of side-effects. Al-
though these agents interfere with two important hypertensive 
factors, i.e. sodium-volume homeostasis and renin secretion, 
their blood pressure lowering effect is insufficient in a 
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considerable number of hypertensive patients, especially in 
those with renal insufficiency. Reduction of the peripheral 
resistance is then indicated, irrespective of the cause of the 
elevation of this resistance. This goal can be achieved with 
alpha-adrenoceptor blocking drugs, but these drugs produce 
serious side-effects, inherent to their mechanism of action, of 
which orthostatic hypotension is the most troublesome. Direct-
ly acting peripheral vasodilators, if used as a single agent, 
induce sodium retention and increases of heart rate, cardiac 
output, and plasma renin activity (25). These reactions not 
only counteract the antihypertensive effect of vasodilators, 
but may also cause serious side-effects such as oedema, palpi-
tations, and headache. Since diuretics promote sodium excretion 
and beta-blockers reduce heart rate, cardiac output and plasma 
renin activity, it is logical to combine these agents with 
vasodilators. Hydralazine, one of the first and best known 
vasodilators, could hardly be used in clinical practice, before 
beta-blockers became available. However, hydralazine, even in 
combination with a beta-blocker and a diuretic, does not always 
lower blood pressure sufficiently (26) and may furthermore 
cause side-effects, unrelated to the haemodynamic reactions. 
Consequently, there was still a need for other, more potent 
vasodilators with fewer side-effects. We have studied the effects 
of minoxidil, a newly developed potent vasodilator, and prazo-
sin, originally also announced as a directly acting peripheral 
vasodilator, in the chronic treatment of hypertension. 
Not only during chronic treatment of hypertension, but also 
after rapid blood pressure reduction in emergency cases vaso-
dilators may sometimes cause problems (27). The potent vaso-
dilator diazoxide has been especially recommended for hyper-
tensive emergencies because of its prompt and long-lasting 
blood pressure lowering effect (28) . However, life threatening 
complications of the use of diazoxide in these situations have 
been reported (27). They were on the one hand caused by the 
exaggerated fall in blood pressure with consequent hypoperfusion 
of vital organs, and on the other hand by cardiac ischaemia as 
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RPP 
SO t i m e (mm) 
Ш diQZOxide 4 3 · 1 0 " 4 Μ 
Ш verapamil 5 - Ю - 5 M 
Й nifedipine 1 · I O - 6 M 
Figure 1. The e f f e c t s of d iazoxide, verapamil and n i f e d i p i n e on r e n a l 
I perfusion p r e s s u r e (RPP) a f t e r barium induced v a s o c o n s t r i c t i o n 
(by cour tesy of P r o f . d r . J . F . G . S i e g e r s ) . 
a consequence of tachycard ia . In an attempt to circumvent these 
s i d e - e f f e c t s we have re-evaluated the supposed necess i ty to 
administe.r diazoxide in hypertensive c r i s i s as a bolus i n j e c t i o n 
and we ha've inves t iga ted the p o t e n t i a l advantages of combining 
diazoxide under these circumstances with a beta-blocker . 
Although the p o s i t i v e r e s u l t s with minoxidi l and diazoxide 
have i n c r e a s e d our t h e r a p e u t i c p o t e n t i a l , t h e r e i s s t i l l a need 
for v a s o d i l a t o r s with l e s s s i d e - e f f e c t s . In recent years more 
a t t e n t i o n has been paid t o the p i v o t a l r o l e of calcium in vas­
cular.- smooth muscle contract ion (29). I t appeared t h a t the 
calcium content of vascular smooth muscle in severa l types of 
h y p e r t e n s i o n i s abnormally high (16). In hypotheses deal ing 
witbi a decreased a c t i v i t y of Na-K-ATPase as a bas ic defect 
in Hypertens ion, the abnormal vascular tone has been p a r t i a l l y 
Π ι 
ascribed to an increase of Ca -ion influx in these cells (30). 
Wit .h regard to these concepts it is attractive to treat hyper-
14 
tension by lowering the concentration of Ca -ions in the vas-
cular smooth muscle cells. Siegers et al. have demonstrated in 
an isolated perfused rat kidney model that diazoxide exerts 
its vasodilating effect by inhibiting the release of these ions 
from intracellular or (sub)membranous stores. In this model he 
also could demonstrate the vasodilating capacity of drugs 
inhibiting the slow-inward calcium current, the so-called 
calcium antagonists. Fig. 1 gives an example of these experi-
ments in which the perfusion flow has been kept constant. Thus, 
increases or decreases of the perfusion pressure reflect in-
creases and decreases of vascular resistance. Vasoconstriction, 
with a consequent increase of the perfusion pressure, is in-
2+ duced by addition of Ba -ions to the perfusate. Diazoxide, at 
-4 
a concentration of 4.3·10 M, reduced the renal perfusion 
pressure from 176 to 120 mmHg, the level measured before the 
2+ addition of the Ba -ions. The same degree of reduction of the 
vascular resistance could be achieved with the calcium antago-
nists verapamil and nifedipine at concentrations in the perfu-
sate of 5·10 M and 1-10 M respectively. Although a high vaso-
dilating capacity on a molar basis of a drug in this model does 
not guarantee a high therapeutic efficacy as a vasodilator in 
man, these results prompted us to investigate the blood pressure 
lowering effect of nifedipine in hypertensive patients. 
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Renin-angiotensin system and blood volume in patients with dialysis-resistant 
hypertension 
F TH M HUYSMANS, TH THIEN* a n d R A P KOENE 
SUMMARY 
Relationships between plasma renin activity (PRA), 
blood pressure response to Saralasin® (AMAPsar) 
and blood volume (BV) were studied in 17 patients 
on chronic haemodialysis Ten out of 12 hypertensive 
patients with a normal or decreased BV showed a 
response to Saralasin (AMAPsar exceeding 10 per 
cent) after maximal dehydration Their blood 
pressures decreased from 160 ± 9/107 ± 5 mm Hg 
to 118 ± 8/78 ± 5 mm Hg during Saralasin infusion 
(AMAPsar - 2 6 8 ± 3 5 per cent) PRA and 
AMAPsar were significantly higher than in five 
normotensive patients, of whom only one showed a 
response to Saralasin A highly significant correla­
tion between initial log PRA an AMAPsar existed 
(r = -076, η = 17) After volume loading in seven 
hypertensive responders, PRA decreased and 
AMAPsar was smaller ( - 7 8 1 3 8 per cent) In each 
instance where a response to Saralasin was ob­
served, PRA increased In five hypertensive res-
ponders the blood pressure became normal after 
bilateral nephrectomy The results show that, in hy­
pertensive dialysis patients, the renin-angiotensin 
system reacts to volume changes and Saralasin in­
fusion as it does in non-dialysed hypertensive pa­
tients The system plays an important role in sustain­
ing dialysis-resistant hypertension The absence of 
a response to Saralasin in this type of hypertension 
can be causd by an increased BV Nelh J Med 25, 
74 
INTRODUCTION 
Hypertension m patients on chronic haemodialysis 
can be treated in most cases by simple ultrafiltration 
during dialvsis", suggesting that its main cause is 
volume overload Some of these patients, however, 
remain hypertensive despite vigorous efforts to re­
move fluid In these patients hypertension can 
nearly always be controlled by bilateral nephrecto­
my 1 9 Although this so-called dialysis-resistant hy­
pertension is generally ascribed to activation of the 
remn-angiotensin system, the plasma renin activity 
(PRA) is not a reliable guide to predict the effect of 
brlatcral nephrectomy on blood pressure" This is 
Department of Internal Medicine Division of Nephrology 'Out 
probably related to the difficulty to perform PRA 
measurements in dialysis patients under standardiz­
ed conditions of fixed sodium intake and/or diuretic 
treatment Moreover, it is not clear, whether, in 
dialysis patients, angiotensin has a similar influence 
on blood pressure as in non-dialysis patients5 Sa­
ralasin®, a specific, competitive inhibitor of angio­
tensin II seems to be a useful drug to assess the role 
of angiotensin in the maintenance of dialysis-resis­
tant hypertension 8 1 6 We have therefore studied 
the relationships between PRA, blood volume (BV) 
and the effect of Saralasin in 12 hypertensive pa­
tients, and compared these results with measure­
ments in five normotensive patients on haemo­
dialysis Our results indicate that dialysis-resistant 
hypertension is caused in most instances by activa­
tion of the renin-angiotensin system The system 
reacts to volume changes and to Saralasin infusion 
as it does in non-dialysed patients 
PATIENTS AND METHODS 
All the patients studied had terminal renal failure 
and underwent regular haemodialysis during 12 to 
14 hours weekly In 12 patients the hypertension 
could not be controlled by ultrafiltration Supine 
diastolic blood pressures before haemodialysis were 
always higher than 95 mm Hg, which level was taken 
as the upper limit of normal in dialysis patients The 
blood pressure (mean ± SD) of these 12 patients, 
measured with a sphygmomanometer before 
haemodialysis was 184 ± 19/111 ± 13 mm Hg su­
pine, and 174 ± 20/110 ± 13 mm Hg while standing 
(mean values of the last three weeks before the start 
of the study) Seven patients showed signs of hy­
pertensive retinopathy and two others had diabetic 
retinopathy Six showed ECG changes consistent 
with a diagnosis of left ventricular hypertrophy1 4 
All antihypertensive drugs had been discontinued 
during at least three weeks before the study 
In a control group of five patients, blood pressure 
was easily controlled by ultrafiltration In this group 
the blood pressure (mean ± SD) before haemo­
dialysis was 147 ± 19/86 ± 5 mm Hg supine and 146 
± 15/86 ± 6 mm Hg while standing Signs of hy­
pertensive retinopathy and left ventricular hyper-
tient Clinic Si Radboud Hospital University of Nijmegen 
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TABLt I CLINICAL DATA OF 17 PAnFNTS 
Number 
Diagnosis 
chronic glomerulonephritis 
chrome pyelonephritis 
(primary 9) malignant hyper 
tension 
diabetic nephropathy 
analgesic nephropathy 
unknown 
Age (years)* 
Months on haemodialysis 
H\penensi\e 
patients 
12 
4 
I 
2 
2 
3 
40 ( 
I 0 ( 
1762) 
1 28) 
\ormotensi\e 
patients 
5 
4 
1 
16(21 46) 
12 ( 3 I?) 
ornean values (ranges m brackets) 
trophy were absent in these five normotensive pa­
tients None of the 17 patients studied showed any 
clinical or radiological sign of overhydration Other 
relevant clinical data are shown in Table I 
The patients were studied 18 h after haemodialy­
sis The hypertensive patients hdd been maximally 
dehydrated until hypotension during haemodialysis 
had made further fluid removal impossible The 
patients were supine during the study and blood 
pressures were measured at two-minute intervals 
with an Artenosonde 1217 from 30 mm before to 30 
mm after Saralasin infusion The heart rate was re­
corded electrocardiographically at ivminute inter­
vals Plasma volume was determined by a 1 2 5 I al­
bumin dilution method after at least 20 mm of re­
cumbency to achieve a stable situation6 BV was 
calculated from the plasma volume and the simul­
taneously determined hacmatocrit, and was ex­
pressed as percentage of the value expected in normal 
adults on the basis of height, weight and sex1 2 
Thereafter, Saralasin was continuously infused at 
three consecutive rates of о 5 - 5 о - io o^g/min kg 
body weight during is mm each Blood samples for 
determination of PRA 3 were drawn immediately 
before and at the end of Saralasin infusion 
In seven hypertensive patients the study was re­
peated after volume loading by saline infusion or by 
avoiding fluid withdrawal during the previous 
haemodialysis One patient was studied a third time 
after less intensive volume loading In five hyper­
tensive patients bilateral nephrectomy was per 
formed, and in two of them Saralasin infusion was 
repeated after the operation 
The antihypertensive effect of Saralasin was 
evaluated by comparing the mean values of the last 
five blood pressures before Saralasin infusion, with 
three blood pressures recorded at the end of each 
dose period Mean arterial pressure (MAP) was cal­
culated as the sum of the diastolic and one-third of 
the pulse pressure A response to Saralasin was de­
fined as a decrease in MAP during Saralasin infu­
sion (AMAPsar) by more than 10 per cent Results 
are expressed as mean ± SEM Statistical methods 
used were Student's t-test for paired and unpaired 
observations and Wilcoxon's test for paired and un­
paired observations Linear correlations were de­
termined according to Pearson A p-valuc < о 05 
was regarded as the level of statistical significance 
RESU1TS 
Ten of the 12 patients with dialysis-resistant hyper­
tension and only one normotensive patient showed 
a response to Saralasin In the 10 hypertensive re-
sponders, blood pressure decreased from 160 ± 9/107 
± 5 mm Hg before Saralasin infusion to 118 ± 8 78 
± 5 mm Hg during the maximal infusion rate This 
decrease was from 144 ± 2/98 ± 3 mm Hg to 140 ± 
o'gs ± 2 mm Hg in the two other hypertensive pa­
tients and from 116 ± 6'78 ± 3 mm Hg to 114 ± 
7/76 ± 4 mm Hg in the normotensive patients 
Seven hypertensive responders were subjected to 
volume loading This did not lead to any clinical sign 
of overhydration, except in one patient with a BV of 
123 per cent, who developed slight dyspnoea We 
found significant increases in body weight and BV, 
and significant decreases in PRA and AMAPsar in 
these seven patients (Fig 1) 
The mean values of PRA, BV and AMAPsar in 
hypertensive responders (before and after volume 
TABLE II BLOOD VOLUMF INITIAI P R A AND EFFECT OF SARALASIN ON BLOOD PRESSURE ( A M A P S A R ) IN DIALYSIS PATIENTS 
\umberof Blood volume' PRA" AMAPsar' 
paiients /"/< ) (ngiomljhi (%} 
Normotensives 
Hypertensive responders before volume loading 
Hypertensive responders after \olume loading 
91 7 ± 4 I 
88 8 ± 1 s 
10s 6 ± 19 
176 ± 82 
1196 ± 180 
101 + 79 
22 ± 16 
-268 ± 1 s 
- 7 8 - 3 8 
•Means ± SEM are given 
••Significant difference ρ < ο οι 
•••Significant difference ρ < o ooi 
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Δ body w e i g h t btood vo lume M A P P R A 
( n g / I O r r l 3 h ) 
Δ M A P j o r 
Fig I Bod) weight blood volume MAP PRA and decrease of MAP during Sjralasin (ДМАРчаг) before (b) and attcr (a) \olume 
loading in sc\cn hvpertcnsive patients 
RR ( m m H g ) p a l 1 6 0 8 5 0 < f 
w e i g h t 6 2 5 kg 
, „ b l o o d vol 8 4 ·/. 
6 5 4 Kg 
1 0 0 ·/. 
6 6 8 kg 
113 ·/» 
H IT 
i l 
15 3 0 4 5 
P R A 1800 
( n g / 1 0 m l 3 n ) 
Э03 5 5 7 Ю10 3 2 8 
fig 2 The effect of Saralasm on blood pressure and PRA at three different blood \olumcs in the same patient Note the decrease of 
PRA and the diminished rise during Saralasm when blood volume increases 
loading) and in normotcnsivc patients are given in 
Table II Before volume loading, AMAPsar and 
PRA, but not BV, were significantly different from 
the values in the normotensive patients After vol­
ume loading these differences disappeared, al­
though BV now tended to be higher in the volume-
loaded patients (p < о oy) In the two hypertensive 
non-responders AMAPsar was - 4 per cent and - 2 
per cent, PRA was low (112 and 16 ng/10 ml/3 h, 
respectively) and BV was 98 per cent and 92 per 
cent, respectively One of these non-responders had 
a diabetic nephropathy and the other had chronic 
pyelonephritis Fig 2 shows the results in the 
patient studied on three occasions AMAPsar was 
-30 per cent, -24 per cent and 0 per cent, respec­
tively, with increasing body weights 
Determination of the relationship between initial 
log PRA and AMAPsar in the 17 Saralasm infusions 
given without volume loading, revealed a highly 
significant correlation (y = —17 6x + 27 4, r=—0 76, 
ρ < ο οοοι ) When all 25 infusions were considered, 
the correlation was similar (y = - i 8 5X+31 4, 
r = - 0 73 p < o o o o i , F i g 3) 
In all cases where a response to Saralasm was 
seen, MAP differed significantly at all three infusion 
rates from MAP in the foregoing period AMAPsar 
was -11 7± 1 7 per cent, —19 4±2 2 per cent and 
-23 9±2 6 per cent, respectively, at increasing in­
fusion rates (p < 0005) PRA rose significantly 
113 1 ±30 3 per cent during Saralasm infusion (p < 
0 0025) In the cases with no response to Saralasm 
we observed no significant changes in MAP or 
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AMAPsarW.) 
Ηθη 
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Fig ι The relationship between log PRA and percentual de 
crease of MAP during Saralasm (ΔΜAPsar) in five normotensive 
dialysis patients (circles) m 12 hypertensive dialysis patients be 
fore (dots) and in 7 after volume loading (triangles) 
PRA Mean heart rates did not change during Sa­
ralasm infusion either in the responders or in the 
non-responders 
In the five hypertensive responders who un­
derwent bilateral nephrectomy, blood pressure be­
came easily controllable by ultrafiltration In two of 
them Saralasm infusion was repeated at about the 
same BV as before the operation (86 per cent and 
89 per cent in the one and 77 per cent and 78 per 
cent in the other patient) In contrast to the reaction 
before nephrectomy, blood pressure now rose dur­
ing Saralasm infusion, whereas PRA was low and 
remained unchanged This rise in blood pressure is 
caused by the weak agonistic effect of Saralasm1 8 
DISCUSSION 
In most of the hypertensive patients in this study the 
blood pressure, which had not decreased to normal 
after maximal dehydration, became normal during 
Saralasm infusion This suggests that the remn-an-
giotensm system plays an important role in sustain­
ing hypertension under these circumstances The 
effect of bilateral nephrectomy on blood pressure, 
AMAPsar and PRA also fits in this concept The 
hypertension in the two patients who showed no 
response to Saralasm, could not be explained by 
hyperactivity of the renin-angiotensin system It is 
also unlikely that hypervolacmia was responsible 
Although the BV in these patients was close to 
normal (98 per cent and 92 per cent), the patients 
were maximally dehydrated because further ul­
trafiltration during haemodialysis had invariably led 
to hypotension The cause of the hypertension in 
these two patients thus remains obscure 
Although blood pressure remained increased af­
ter increasing the BV in seven hypertensive res­
ponders, the PRA decreased in all and AMAPsar in 
six out of seven This shows that the renin depen­
dency of dialysis-resistant hypertension can be sup­
pressed by volume loading, as has been suggested by 
o t h e r s 1 0 1 1 1 5 The effect of volume loading was 
most clearly demonstrated in the patient studied at 
three different blood volumes A similar interre­
lationship between fluid balance and activity of the 
renin-angiotensin system has been reported in non-
dialysed patients with hypertension2 4 2 0 The initial 
PRA and AMAPsar were higher in the hyper­
tensive responders than in five normotensive 
patients, whereas blood volumes were not signifi­
cantly different This suggests that PRA is inap­
propriately high in the hypertensive responders Af­
ter volume loading of the hypertensive responders 
these differences in PRA and AMAPsar disappear­
ed, but now the BV tended to be higher in the 
hypertensive group PRA increased in responders 
but did not change in non-responders during Sara­
lasm infusion This reaction of renin secretion is also 
similar to that found in non-dialysed hypertensive 
patients7 The correlation we found between PRA 
and AMAPsar in dialysis patients has been reported 
e a r l i e r ' 1 1 1 7 It is, however, of interest that this 
correlation is quantitatively the same as that found 
in non-dialysed patients by THIEN et al, who used the 
same protocol This is reported elsewhere in this 
issue We did not find an influence of Saralasm on 
the heart rate, despite marked reductions in blood 
pressure This phenomenon, reported in many other 
studies, remains to be explained1 1 3 
We conclude that, in dialysis patients with hy­
pertension, the renin-angiotensin system can be 
suppressed by volume loading and stimulated by 
Saralasm as in non-dialysed hypertensive patients 
The relation between PRA and effect of Saralasm 
on blood pressure in dialysis and non-dialysis 
patients is also similar High blood pressure in 
dialysis patients that does not disappear after 
maximal volume depletion, is sustained by activa­
tion of the renin-angiotensin system in most cases 
24 
This role of the renin-angiotensin system can only 
be assessed after maximal dehydration, since vol­
ume overload may suppress its activity This volume 
overload may be present without clinical signs of 
overhydration Therefore, hypervolaemia has to be 
carefully excluded before a diagnosis of dialysis-re­
sistant hypertension is made Determination of 
PRA and use of the Saralasin test will be helpful in 
establishing the diagnosis By this approach, un­
necessary treatment with antihypertensive drugs or 
bilateral nephrectomy in dialysis patients who ac­
tually have volume-dependent hypertension, can be 
avoided 
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SUMMARY 
The potent arterial vasodilator minoxidil was used in 35 hyper-
tensive patients, 17 with moderate (group 1) and 18 with severe 
(group 2) hypertension. In group 1 minoxidil (mean dose 26 mg 
daily) was added to chlorthalidone. Mean supine blood pressure 
decreased from 164/112 to 156/90 mmHg. With increasing doses 
of minoxidil, the addition of a B-blocker was necessary in 
most patients. This led to a further decrease of blood pressure 
to 139/86 mmHg. Mean supine heart rate increased from 84 to 93 
beats/min, but decreased to 74 beats/min after addition of pro-
pranolol. In group 2 minoxidil (mean dose 37 mg daily) was 
added to a diuretic and a ß-blocker, and the mean supine blood 
pressure decreased from 197/126 to 165/100 mmHg. Sodium reten-
tion occurred in all patients. The consequent oedema that de-
veloped in several patients could be treated with furosemide. 
The most important side-effects were hypertrichosis (69%), 
fatigue (26%) and nausea (20%), and this necessitated inter-
ruption of treatment in six patients. 
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INTRODUCTION 
We have previously shown that the peripheral vasodilator dia-
zoxide effectively lowered blood pressure in patients with 
severe hypertension, when used in combination with a ß-blocker 
and a diuretic (1). The drug has, however, undesirable side-
effects of which hyperglycaemia and hypertrichosis are the 
most important. Thus, there is a continuing need for better 
vasodilating drugs. Minoxidil is such a new and potent vasodi-
lator which can be used orally. In this paper we describe our 
experience with minoxidil in patients with moderate and severe 
hypertension, with particular emphasis on its activity in com-
parison to diazoxide. 
PATIENTS AND METHODS 
From 1975 on, we have treated 35 patients with minoxidil. The 
clinical data are given in Table 1. In group 1, consisting of 
patients with moderate hypertension during chlorthalidone 
treatment (mean supine blood pressure 164/112 mmHg), minoxidil 
was added to the existing regimen. The starting dose was 2-5 
mg and this was rapidly increased until a maximum of 45 mg 
(b.i.d. or t.i.d.) or a diastolic blood pressure of less than 
85 mmHg was reached. The blood pressure was measured with a 
stamped sphygmomanometer, after at least 5 minutes of recum-
bency (two readings) and after 1-2 minutes of standing. We 
also measured supine and standing pulse rates and body weight 
at each clinic visit. When the supine pulse rate exceeded 100 
beats/min at two subsequent visits or when the patients com-
plained of palpitations, propranolol (120-320 mg daily) was 
added. We substituted furosemide for chlorthalidone when 
oedema developed or when the increase in body weight amounted 
more than 3 kg. Salt intake was unrestricted. Laboratory exa-
minations, electrocardiograms and chest X-rays were performed 
regularly. In most patients we performed echocardiograms to 
check for the presence of pericardial effusions that can occur 
during minoxidil treatment. All clinical and laboratory data 
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Table 1. C l i n i c a l d a t a of 35 p a t i e n t s t r e a t e d with minoxidi l 
Nature of hypertension 
moderate severe 
(group 1) (group 2) 
Number of p a t i e n t s 17 1Θ 
Sex 
male 11 16 
female 6 2 
Age ( y e a r s ) * * * 38 + 1 3 43 + 12 
Cause of hyper tens ion: 
r e n a l parenchymatous 12 6 
renovascular 3 0 
e s s e n t i a l 2 12 
C r e a t i n i n e c learance (ml/min)*** 74 +^16 55 +_ 38 
Left v e n t r i c u l a r hypertrophy 8 13 
Hypertensive r e t i n o p a t h y * * 6 14 
Previous phase of malignant hypertension 1 7 
Number of drugs prev ious ly used 4 +_ 2 7 +_ 3 
# e l e c t r o c a r d i o g r a p h i c c r i t e r i a according t o Romhilt and Estes (2) 
*» according t o Keith e t a l . (3) 
»»«mean values ± S.D. 
used for eva luat ion were the means of the observations on a t 
l e a s t three d i f f e r e n t v i s i t s during the use of a constant drug 
dosage, 
Group 2 consis ted of p a t i e n t s with severe hypertension during 
d i u r e t i c treatment and ß-adrenergic blockade (mean supine blood 
pressure 197/126 mmHg). In most of these p a t i e n t s previous 
treatment with o ra l diazoxide had i n s u f f i c i e n t l y cont ro l led 
blood p ressure , or a l t e r n a t i v e l y hype r sens i t i v i ty to diazoxide 
had developed. After discontinuance of diazoxide we measured 
blood pressure on th ree c l i n i c v i s i t s before s t a r t i n g minoxidil 
in a dose of 15 mg d a i l y . This was increased to a maximum of 
75 mg dai ly depending on the blood pressure response. Mean 
a r t e r i a l pressure (MAP) was ca lcu la ted as the sum of the d ia -
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stolic and one third of the pulse pressure. The correlation 
coefficient calculated according to Pearson (Documenta Geigy: 
Scientific tables) was used for statistical evaluations. 
RESULTS 
Table 2 shows the antihypertensive effect of minoxidil. In 
group 1 minoxidil (mean dose 26 mg daily) caused a 13.2% drop 
in MAP (supine) and 14.5% (standing). In 11/17 patients (group 
1A, Table 2) the addition of a ß-Ыоскег was necessary (the 
remaining six patients stopped minoxidil before the ß-blocker 
could be started). This led to a further decrease in MAP of 
9.6% (supine) and 8.7% (standing). After a mean treatment 
period of 2 years the antihypertensive effect of this combina-
tion was unchanged: mean blood pressure 139/86 mmHg supine and 
133/93 mmHg on standing. The only change in the treatment sche-
dule consisted of replacement of chlorthalidone by furosemide 
because of the increase in body weight in five patients. In the 
patients with severe hypertension (group 2) the effect of mi-
noxidil (mean dose 37 mg daily) was even better (Table 2) with 
a mean MAP decrease of 18.7% (supine) and 18.9% (standing). 
There were minor changes in the treatment schedule i.e. an in-
crease in the daily dose of propranolol from 309 to 344 and 
a replacement of chlorthalidone by furosemide (mean dose 180 
mg daily) in four patients. This latter change could not pre-
vent a 2.3 kg increase in body weight in the whole group. Des-
pite this there was a good hypotensive effect. In 18 patients 
(six in group 1, 12 in group 2) we could compare the antihyper-
tensive effect of minoxidil (36 mg daily) to that of oral 
diazoxide (278 mg daily). The results depicted in Figure 1 
suggest that the effects of minoxidil were slightly better 
than those of diazoxide in spite of a greater rise in body 
weight. Eight patients stopped taking minoxidil, while conti-
nuing all other drugs. In this group the mean blood pressure 
level returned to its pretreatment value (mean supine blood 
pressure 186/113 mmHg before, 163/87 mmHg during and 184/110 
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mmHg a f t e r m i n o x i d i l ) . 
180 
160 
RR(mmHg)
 n (meamSEM) ™u 
supine 
standing 12O 
100-
80- 1 
HR (beats / min) 
n=18 
supine 
standing 
Body weight 
(kg) 
Creatinine 
(ДІМ/І) 
70-
79-
7 7 -
300 
250 3 
diazoxide 
(278 mg) 
J 
minoxidil 
(36 mg) 
Figure 1. Comparison of the effects of diazoxide and minoxidil added to the 
same doses of ß-blocker and d iure t ics . Means of the readings on 
three v i s i t s were used. 
SIDE-EFFECTS 
Seven p a t i e n t s d i s c o n t i n u e d t r e a t m e n t because of s i d e - e f f e c t s 
( s i x i n group 1, one i n group 2 ) . Four female p a t i e n t s s topped 
because of h y p e r t r i c h o s i s , two p a t i e n t s s topped because of 
nausea and vomi t ing t h a t p e r s i s t e d a f t e r p ro longed u s e , and 
one p a t i e n t had s e v e r e n o c t u r n a l c o m p l a i n t s of p a l p i t a t i o n s 
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Table 2. Effect of minoxidil on blood pressure (BP, mmHg) and heart rate (HR, beats/min) 
Before minoxidil 
Minoxidil and 
chlorthalidone 
Minoxidil with 
diuretic and B-blocker standing 
supine 
standing 
supine 
standing 
supine 
group 1 
(n=17) 
BP 
164/112* 
(20/9) 
161/116 
(16/8) 
156/90 
(16/10) 
148/94 
(13/12) 
HR 
82 
(13) 
95 
(17) 
91 
(И) 
100 
(15) 
group 1A 
(n=ll) 
BP 
160/114 
(19/11) 
158/118 
(12/10) 
153/95 
(16/8) 
147/99 
(13/11) 
137/86 
(17/7) 
134/91 
(17/8) 
HR 
84 
(10) 
97 
(12) 
93 
(11) 
102 
(13) 
74 
(7) 
80 
(7) 
group 2 
(n=18) 
BP 
197/126 
(13/14) 
187/128 
(31/14) 
165/100 
(24/12) 
161/100 
(27/13) 
HR 
71 
(7) 
76 
(8) 
73 
(7) 
76 
(6) 
* mean value, S.D. in parentheses. 
despite a high dose of ß-blocker. Figure 2 shows that we did 
not observe significant orthostatic hypotension. Weight gain, 
often leading to overt oedema occurred in all patients and was 
correlated with the dose of minoxidil (r = 0.68, P<0.001). 
There was no correlation between weight gain and initial renal 
function. Despite treatment with increasing doses of furosemide 
(up to 1000 mg daily), an increase in body weight occurred in 
most patients of either group. Palpitations were observed in 
group 1 in almost all patients, but were slight and transient 
in group 2. Hypertrichosis was the most troublesome side-effect 
(71%), especially in young female patients. Other side-effects 
were fatigue (seven patients in group 1 and two in group 2) and 
nausea (five and two respectively). Muscle cramps and faintness 
were also mentioned. 
MAP y (mmHg) 
1ΘΟ 
160 
140-
120 
100-
/ " I I 1 I 
Θ0 100 120 140 160 1Θ0 
MAPo—«(mmHg) 
Figure 2. Absence of significant orthostatic hypotension during minoxidil; 
mean of three controls, supine and standing. 
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CLINICAL TESTS 
We observed no changes in haematological parameters, and anti-
nuclear antibodies did not develop. Fig. 3 shows that there was 
Creatinine (pM/l) 
2000 
1000 
800 
600 
400 
200 
100-
80-
60-
0 
before maximal chronic 
treatment increase treatment 
Figure 3. Effect of minoxidil on plasma creatinine levels. 
a slight, but transient increase in creatinine, which was always 
seen in the first two months of treatment. Hyperglycaemia that 
often occurs during diazoxide treatment did not develop with 
minoxidil. In most patients we observed a transient increase 
in lactodehydrogenase levels, without concomitant electrocar­
diographic changes. There were no signs of haemolysis or dis­
turbances of liver function. Minor electrocardiographic signs 
of increased ischaemia were seen in only two patients and were 
temporary. Echocardiograms were carried out in 20 patients 
after prolonged use of minoxidil, all without signs of peri­
cardial effusions. 
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DISCUSSION 
Minoxidil, a piperidine-pyrimidine derivative, is a directly-
acting vascular smooth muscle relaxant. It is orally effective 
and has a plasma half-life of about four hours. The effect on 
blood pressure lasts much longer, which is most likely caused 
by binding of minoxidil to the vascular receptor sites (4). 
This study shows that minoxidil effectively lowers blood 
pressure, especially when added to a B-blocker (group 2). As 
expected with a vascular smooth muscle relaxant, orthostatic 
hypotension was not a problem. It could also be expected that 
^-blockade and diuretics would be necessary to antagonize the 
compensatory reactions i.e. reflex tachycardia and sodium re-
tention. Brunner et al. (5) stated that it was possible to 
stop or at least to decrease the total daily dose of ß-blocking 
drugs after a few months of treatment with minoxidil. Although 
we have observed this in a few patients, we have also seen the 
contrary. Some patients showed an increased need for ß-blocking 
drugs during minoxidil, even after several months of treatment. 
Most reports on minoxidil are confined to the treatment of re-
fractory hypertension (6). Our results show that the drug is 
also effective in patients with moderate hypertension. Minoxi-
dil compared favourably with diazoxide in our study. It should 
be noted that the patients studied were not unselected since 
one of the criteria was an unsatisfactory response to diazoxide. 
On the other hand the antihypertensive effect of minoxidil was 
obtained in spite of a greater increase in body weight and in 
spite of a progression of the hypertensive vascular and/or 
renal disease. The high frequency of hypertrichosis makes it 
difficult to use the drug in female patients. This also holds 
for oral diazoxide (1). Unlike diazoxide, minoxidil did not 
cause hyperglycaemia in our patients and this is in accordance 
with the literature. This could be another argument in favour 
of minoxidil but one should be cautious to make definite 
choices at this moment, since the experience with this new 
drug is still limited. Other side-effects such as, possibly, 
pericardial effusions may appear after long-term use. However, 
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these effusions were found most frequently in patients with 
renal insufficiency (7) and it is possible that the combined 
effects of uraemia and sodium retention were responsible. It 
remains unclear whether minoxidil by itself can cause pericar-
dial effusion. In any case, we have not seen this complication 
in our patients. In accordance with others (5,8) we did not 
find a deterioration in renal function after long term use. 
The slight, initial increase in creatinine that accompanied 
the rapid fall in blood pressure during the first weeks of 
treatment was transient in almost all patients. Electrocardio-
graphic changes have been described which occur in the initial 
period when blood pressure drops rapidly. Although it is 
tempting to speculate that the transient rise in LDH levels 
was related to myocardialischaemia this seems unlikely since 
it occurred after variable periods of treatment and there 
were no concomitant electrocardiographic changes. The signifi-
cance of this finding remains unclear as yet. 
We conclude that minoxidil is a highly effective drug when 
combined with (J-blockade and in this combination it is well-
tolerated. The antihypertensive action is sustained after 
long-term use. In comparison to oral diazoxide the absence of 
hyperglycaemia is an advantage. The high frequency of hyper-
trichosis and the uncertainty about cardiac effects make it 
advisable to use the drug only when patients are refractory to 
other therapeutic regimens. 
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Chapter IV 
THE ANTIHYPERTENSIVE EFFECT OF PRAZOSIN 
F.Th.M. Huysmans, Th. Thien, J.G.M.C. Rosier, 
A. van 't Laar and R.A.P. Koene 
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Out-patient Clinic, Sint Radboudziekenhuis, University of 
Nijmegen, The Netherlands 
Translated from a publication in the "Nederlands Tijdschrift 
voor Geneeskunde" 124, 1141-1147 (1980) 
SUMMARY 
The antihypertensive action of prazosin was studied in 38 patients 
with arterial hypertension. In accordance with the majority of 
reports in the literature, we observed a very pronounced effect 
on the blood pressure in the erect posture. In the supine posi-
tion, on the other hand, only a slight antihypertensive effect 
was seen. Orthostatic faintness occurred in 28 patients, while 
six suffereda collapse.Accordingly, prazosin probably dilates 
not only the resistance arterioles but also the capacitance 
venules. Three patients complained of urinary stress inconti-
nence. These findings tally with the current opinion that 
prazosin exerts an alpha-sympathicolytic action. 
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INTRODUCTION 
Until beta-adrenoceptor blocking agents became available, 
treatment of hypertension with peripheral vasodilators was not 
very well possible because of the troublesome haemodynamic side-
effects of these agents. The peripheral vasodilation induces 
tachycardia and an increase of cardiac output, which are often 
accompanied by palpitations, severe headache and in some patients 
even by anginal complaints. These side-effects can be largely 
prevented by beta-adrenergic blockade (1,2). The hitherto known 
vasodilating agents sometimes have other serious side-effects 
than the above-mentioned. For instance, hydralazine can cause 
a lupus-like syndrome (3) . Diazoxide can provoke hypertrichosis 
and hyperglycaemia (4). Minoxidil, a promising not yet registered 
vasodilator, has been reported to give also hypertrichosis and 
moreover exudative pericarditis (5,6). Therefore, there is still 
a need for a new, effective peripherally vasodilating agent 
with low toxicity. In 1976 prazosin-hydrochloride (Minipress), 
a quinazoline derivative, not related to any other antihyper-
tensive agent, has been introduced as such a vasodilator. One 
of the most important reported side-effects is the so-called 
first dose phenomenon, which is characterized by severe dizzi-
ness, palpitations, and sometimes even a collapse after the 
ingestion of the first tablet. This complication is probably 
caused by orthostatic hypotension (7,8). The phenomenon suppo-
sedly occurs more readily in patients with a diminished \extra-
cellular volume (9) and less frequently at a low initial dose 
(10). Especially in renal insufficiency this initial dose 
should be kept low and only gradually increased (11). From 1974 
we have used prazosin in 38 hypertensive patients with arterial 
hypertension. We report here on the antihypertensive efficacy 
and side-effects of this agent. 
PATIENTS AND METHODS 
We have studied 38 patients with hypertension, defined as a 
diastolic blood pressure above 90 mmHg (mean of three measure-
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Table 1. Clinical data of 38 patients (22 males and 16 females) 
Number of patients 
Cause of hypertension 
parenchymatous renal disease 
renovascular 
essential 
Organ damage 
retinopathy* 
left ventricular hypertrophy** 
renal function: 
endogenous creatinine clearance <50 ml/min 
endogenous creatinine clearance >50 ml/min 
Age (years) 
Dose of prazosin (mg/day) 
Duration of treatment (months) 
* According to the criteria of Keith et al (12). 
** According to the criteria of Romhilt and Estes (13). 
*»» Mean value, range in parentheses. 
ments at three consecutive occasions in the outpatient clinic). 
Twenty-seven of these patients used already one or two anti-
hypertensive agents. Table 1 shows the most important clinical 
data, the mean prescribed dose of prazosin (divided in two or 
three doses a day) and the duration of the observation period. 
In patients who were already treated with other antihyperten-
sive agents, the dose of these agents was kept constant. All 
patients were treated in the out-patient clinic and had no salt 
restriction. 
At each visit blood pressure (Erkameter 300) and pulse rate 
were measured after five min in the supine position and after 
one min of standing; Korotkoff phase V was taken as the dia-
stolic blood pressure. To assess the antihypertensive effect 
22 
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of prazosin we compared in each patient the mean of the blood 
pressure values of the last three visits before prazosin 
therapy with the mean of the last three visits at a constant 
dose of prazosin, always at least four weeks after the start 
of this treatment. The percentual decrease of the mean 
arterial pressure (MAP = diastolic blood pressure + one third 
of the pulse pressure) was calculated from the same blood 
pressure values. Blood pressures measured at the first four 
visits were not taken into account, because there is often a 
spontaneous decrease during this period (14). In 14 out of the 
38 patients we measured the blood pressure at gradually in-
creasing doses of prazosin, on each occasion during half an 
hour every two minutes with an automatic device (Arteriosonde 
1217) . These data were used to devise a dose-effect curve. 
Means of body weights, plasma creatinine levels and endogenous 
creatinine clearances were calculated from three measurements 
each, made before, during and after prazosin therapy. Once 
every two to three months we checked haemoglobin concentration, 
leukocyte and differential count, plasma sodium, potassium, 
bicarbonate, chloride and blood glucose levels, serum transami-
nases and alkaline phosphatase levels and the anti-nuclear 
factor. Statistical comparisons were made with Student's t-test 
for paired and unpaired observations. 
RESULTS 
The effect of prazosin on blood pressure. Table 2 shows the 
decrease of blood pressure during prazosin treatment. It should 
be noted that the blood pressure decrease was small in the su-
pine position and less (P<0.0001) than on standing. Fig. 1 
shows the individual data on the orthostatic change of MAP 
before and during prazosin treatment. After discontinuation of 
prazosin therapy blood pressure increased to its pretreatment 
level in a group of 26 patients, in whom this could be investi-
gated. 
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Table 2. Effect of prazosin on blood pressure in 38 patients 
Period Blood pressure* (mmHg) 
Supine Standing Supine Standing 
systolic diastolic systolic diastolic 
Before prazosin administration 168jf4 108 jf 2 162 + 4 113 + 2 
During prazosin administration 163 +_ 4 104 +^  2 144 +_ 4 101+2 -4 -11 
After*** prazosin administration 171+5 110+3 161+4 114+3 
* Mean values ± S.E.M. 
«* MAP: mean arterial pressure (diastolic pressure + 1/3 of pulse pressure). 
#»# In 26 patients, measured at least four weeks after discontinuation of prazosin. 
Decrease of MAP** (%) 
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Figure 1. Mean arterial pressure (MAP) in supine and standing position in 
38 patients before (left figure) and during (right figure) treat­
ment with prazosin. 
Because the effect of prazosin was disappointing in the entire 
group, we examined whether the antihypertensive action of pra­
zosin was larger during concomitant use of other antihyperten­
sive agents. To this end we divided the patients into three 
groups : 
- group 1: 11 patients used prazosin as a single antihyperten­
sive agent; 
- group 2: eight patients in whom prazosin was added to a beta-
adrenoceptor blocking agent (propranolol, mean daily dose 
225 mg); 
- group 3: 17 patients in whom prazosin was added to a combi­
nation of propranolol (mean daily dose 231 mg) and chlortha­
lidone (mean daily dose 94 mg). 
In one patient prazosin was added to propranolol and furosemide, 
in another to propranolol and diazoxide; for this reason they 
were not assigned to one of these three groups. Fig. 2 shows 
that also in these three separate groups the antihypertensive 
effect of prazosin is small. In each group the antihypertensive 
45 
blood 2 0 0 -
pressure 
( m m Hg) 
Π supine 
D standing 
160 
120-
Θ0 
prazosin 
1 
ДА 
I, 
τ 
before during after 
4
 ν ' 
n=11 n=5 
іЗ-Ыоскег 
+ 
prazosin 
Ài 1 ώ 
li 
Jr 
Tf 
Δ M A P supine 
( % ) standing 
-1 
-9 
before during a f t e r 
* ν ' 
- 3 
- io 
diuretic 
β- blocker 
prazosin 
д. Д. 
Д, 
before during a f t e r 
' ν ' 
n»17 n = 14 
- 7 
-13 
г 2 0 0 
160 
120 
L 8 0 
Figure 2. The antihypertensive effect of prazosin in three groups of 
patients on different therapeutic regimens before, during, and 
after treatment. Mean values ± S.E.M. are shovm. 
effect in the standing position is larger than in the supine 
position. The blood pressure lowering effect is largest in 
group 3 and smallest in group 1 (P<0.01). Mean blood pressure 
values before and after prazosin treatment in each group did 
not differ in the 24 patients, in whom both these values were 
measured. In group 1, 2, and 3 the average daily dose of pra­
zosin amounted 18, 11, and 12 mg respectively and the mean du­
ration of treatment 3.7, 4.5, and 4.3 months. Therefore, the 
differences in the blood pressure lowering effect of prazosin 
between these three groups cannot be explained by differences 
in doses or duration of treatment. 
In 15 patients with a low endogenous creatinine clearance (<50 
ml/min) MAP in the supine position decreased during prazosin 
treatment by 5% and in 22 patients with a practically normal 
endogenous creatinine clearance (>75 ml/min) MAP in supine 
position decreased by 3%. Consequently, the antihypertensive 
effect of prazosin was not smaller in case of decreased renal 
function. Similarly, we could not find a relation with the pre­
treatment blood pressure level, the nature of the hypertension, 
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Figure 3. The a n t i h y p e r t e n s i v e e f fect of d i f f e r e n t doses of prazos in 
(upper p a r t ) and of prazosin in combination with a beta-adreno-
ceptor blocking and d i u r e t i c agent (lower p a r t ) (automatic blood 
p r e s s u r e recordings in supine p o s i t i o n ) . MAP = mean a r t e r i a l 
p r e s s u r e . Mean values ± S.E.M. a r e shown. 
the age or the sex of the p a t i e n t s i n v e s t i g a t e d . 
The dose-effect curve in Fig . 3 shows t h a t the ant ihypertens ive 
e f fect of prazosin increases when the dose i s gradually ra i sed 
t o 12 mg d a i l y . I t i s a l so apparent from t h i s curve t h a t the 
e f fect of prazos in, i f added t o ch lor tha l idone and a beta-
adrenoceptor blocking agent, i s l a rger than t h a t of prazosin 
a lone. 
Influence on pulse r a t e . In 25 p a t i e n t s pulse r a t e s measured 
on a t l e a s t three o u t - c l i n i c v i s i t s were known. Mean value 
changed l i t t l e in supine p o s i t i o n , from 7 0 + 2 (SEM) t o 69 + 2 
beats per minute during prazosin therapy. On standing the pulse 
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r a t e i n c r e a s e d b e f o r e a s w e l l a s d u r i n g p r a z o s i n t h e r a p y , t o 
7 7 + 2 a n d 7 9 + 3 b e a t s p e r m i n u t e r e s p e c t i v e l y . S e v e n o u t of 
t h e s e 25 p a t i e n t s w e r e on p r a z o s i n w i t h o u t a b e t a - a d r e n o c e p t o r 
b l o c k i n g a g e n t . T a b l e 3 shows t h a t p r a z o s i n d i d n o t r a i s e 
p u l s e r a t e i n t h e s e p a t i e n t s . A f t e r s t a n d i n g d u r i n g o n e m i n 
p u l s e r a t e r o s e m o r e d u r i n g p r a z o s i n t h a n b e f o r e t r e a t m e n t 
( P < 0 . 0 1 ) b u t t h i s l a r g e r i n c r e a s e was a c c o m p a n i e d by a l a r g e 
d e c r e a s e of s y s t o l i c b l o o d p r e s s u r e ( P < 0 . 0 0 2 5 ) . 
Table 3 . Pulse r a t e in supine and s tanding p o s i t i o n and change of pulse 
r a t e and blood p r e s s u r e in seven p a t i e n t s using prazos in alone 
Period Pulse r a t e * Change a f t e r s tanding 
(beats/min) up of p a t i e n t (%) 
Supine Standing Pulse S y s t o l i c blood 
r a t e p r e s s u r e 
Before prazos in a d m i n i s t r a t i o n 78 +_ 3 ΘΘ +^  3 +13 +2 
During prazos in a d m i n i s t r a t i o n 77 + 3 94 +_ 2 +22 -10 
* Mean values ± S.E.M. 
Side-effects. The incidence of complaints mentioned by the 
patients on at least two out-clinic visits and not existing 
previously, is given in Table 4 . The high incidence of dizzi­
ness (74%), occurring especially on standing up and during 
exercise, is striking. This complaint often remained present, 
even after prolonged use of prazosin. Six patients experienced 
a collapse (only one patient on the first day of treatment). In 
the remaining five patients it occurred later, in one even four 
months after the start of the treatment. Two patients had this 
collapse after the intake of only 0.5 mg of prazosin. Only two 
of these six patients used a diuretic agent. Three female pa­
tients developed stress-incontinence. We have reported else­
where (15) that this was caused by a prazosin-induced decrease 
of urethral pressure. 
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Table 4. Side-effects of prazosin in 38 patients 
Phenomenon No. of patients (%) 
Dizziness 
Collapse 
Nausea, vomiting 
Headache 
Fatigue 
Nasal congestion 
Palpitations 
Stress-incontinence 
28 (74) 
6 (16) 
10 (26) 
8 (21) 
17 (45) 
8 (21) 
3 (8) 
3 (8) 
No influence of prazosin on renal function or on body weight 
could be demonstrated. Oedema or hypertrichosis were not ob-
served. None of the patients complained of arthralgias and the 
antinuclear factor did not become positive in any of them. No 
systematically occurring changes were observed in the results 
of the various haematological determinations, the plasma levels 
of sodium, potassium, chloride, bicarbonate or urate, the liver 
function tests or the blood glucose levels. 
DISCUSSION 
The antihypertensive effect of prazosin in this study was 
smaller than one would have expected on the basis of several 
reports in the literature, according to which the antihyper-
tensive effect of 1.0 mg of prazosin is comparable to that of 
40 mg of propranolol, 20 mg of hydralazine or 0.75 mg of ben-
droflumethiazide (16) . Although several patients had decreased 
renal function, this cannot explain the small effect. Some in-
vestigators have even advocated the use of prazosin in the 
treatment of nephrogenic hypertension and of hypertension in 
patients with decreased renal function, because only small 
amounts of the drug are cleared by the kidney (11,17,18,19,20). 
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The dose of prazosin in this study is certainly not low when 
compared to that used in most other studies. Moreover, at 
doses higher than 20 to 30 mg daily an extra antihypertensive 
effect is generally not achieved (16). With two or three gifts 
the dose is sufficiently spread over the day (10). It may take 
maximally six weeks after the start of the prazosin treatment, 
before the effect on blood pressure has completely developed 
(10); consequently, the duration of treatment in our patients 
was sufficiently long. It is of course possible that the drug 
was taken irregularly by our patients, for instance because of 
orthostatic complaints. However, arguments against this are, 
that the orthostatic hypotension and the related complaints 
disappeared in the group of patients, in whom we discontinued 
the prazosin treatment, and that the blood pressure in these 
patients returned to pretreatment levels. 
An explanation for the discrepancy between our findings and 
those of several other studies could be that the position in 
which blood pressure was measured, differed. If blood pressure 
is measured in the sitting or standing patient (21,22,23), the 
antihypertensive action of an agent, of which orthostatic hypo-
tension is a frequently occurring side effect, may easily be 
overestimated. In the large series of Hayes et al. (17) also 
the majority of blood pressure values were measured with the 
patient in sitting or standing position (Hayes, personal 
communication). 
Furthermore, not all the literature reports on prazosin are 
positive. Amëry et al. (24) and Fernandes et al. (25) reported 
a smaller antihypertensive effect of prazosin than of alpha-
methyldopa. Moreover, the first mentioned group only found a 
significant effect if orthostatic dizziness occurred at the 
same time chirger et al. (26) found a smaller influence on 
blood рп ч ire of prazosin than of hydrochlorothiazide. Like 
we did, Falase et al. (27) only found a relevant effect on 
blood pressure in the standing position. 
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Orthostatic hypotension is a well-known side-effect of drugs 
with an alpha-sympatholytic activity. It is not observed during 
treatment with directly acting peripheral vasodilators such as 
hydralazine, diazoxide, or minoxidil (28). Initially, the anti-
hypertensive action of prazosin was also ascribed to direct di-
latation of the resistance arterioles (29) . Subsequent investi-
gations have demonstrated that its effect is attributable to 
an alpha-sympatholytic action (16). Orthostatic dizziness was 
the most frequently occurring side-effect in the group of pa-
tients we have studied. This was not always accompanied by a 
fall in blood pressure and conversely the frequently occurring 
fall in blood pressure on standing did not always induce dizzi-
ness. Yet, it seems likely that both phenomena have the same 
cause, i.e. a decreased constriction of the capacitance venules 
with consequent decrease of the blood supply to the heart, and 
a fall of the cardiac output. Also the collapse, which did not 
only occur after the first dose and which was rather frequently 
observed in comparison to the data from the literature, is pro-
bably due to the same mechanism (8,16). Not only the side-effects 
that we observed, but also the results of the urological exami-
nations during and after the use of prazosin in two out of the 
three patients complaining of stress-incontinence (15), strongly 
suggest, that prazosin indeed has an alpha-sympatholytic effect 
with important clinical consequences. 
A possible advantage of prazosin is the fact that it does not 
raise cardiac output, plasma renin activity, or pulse rate 
(10,30,31,32). Many controversies still exist in this field. 
Especially the absence of a rise in pulse rate is ascribed to 
the fact, that prazosin selectively blocks only the postsynap-
tic alpha,- and not the presynaptic alpha_-adrenoceptors (31). 
These alpha--adrenoceptors mediate the negative feed-back of 
noradrenaline on its own secretion. The classical alpha-sympa-
tholytic agents (such as phentolamine) which block alpha.- and 
alpha_-adrenoceptors, inhibit this negative feed-back with a 
consequenc overflow of noradrenaline into the circulation; this 
excess induces tachycardia. The difference in influence on 
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heart rate between prazosin and the classical alpha-sympathc-
lytic agents can be understood from this difference in selecti-
vity. The question remains, why directly acting vasodilating 
agents such as hydralazine, diazoxide and minoxidil, which 
exert their effect peripherally from the alpha.-adrenoceptors 
and consequently do not induce an overflow of noradrenaline 
from the synaps, either do cause tachycardia (28) in contrast 
to prazosin. A possible explanation is that the antihyperten-
sive effect of prazosin is too small to stimulate peripheral 
sympathetic activity via the baroreceptors. However, when the 
blood pressure decreases largely during prazosin treatment, 
more than was the case in our patients, there is still no 
significant rise in heart rate (10,30,33,34,35). Another 
explanation could be that prazosin causes greater increases in 
sensitivity of the baroreceptors than the above-mentioned arte-
riolar vasodilators. This increased sensitivity could then in-
duce a stronger stimulation of the afferent (inhibiting) path-
ways of the baroreceptor reflex arch leading to a stronger 
inhibition, or alternatively less withdrawal of inhibition, of 
the peripheral sympathetic system. This ultimately leads to a 
smaller increase in heart rate. Indeed this mechanism has been 
described in a study of experimental animals for prazosin, 
hydralazine and minoxidil (31). However, in our patients the 
baroreceptor reflex arch as such was apparently intact since 
a large increase in heart rate was observed during the fall in 
blood pressure on standing up, during treatment with prazosin 
alone (+22%) as well as during combined treatment with prazosin 
and a beta-adrenoceptor blocking agent (+13%). Consequently it 
remains unclear why heart rate does not rise during prazosin 
treatment. This somewhat enigmatic property combined with the 
selectivity for alpha.-adrenoceptors makes prazosin a pharma-
cologically interesting agent. 
In conclusion, we observed, in contrast to many reports in the 
literature, a small effect of prazosin on supine blood pressures. 
Therefore it seems necessary to compare the effectiveness of 
prazosin in an accurately planned cross-over trial with that 
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of several other vasodilating agents, especially hydralazine. 
In such a study much attention must be paid to the influence 
of the position of the patient on the antihypertensive effect 
of the agents. If the impression based on this study, i.e. that 
prazosin is not more effective than hydralazine, would be con-
firmed, one should raise the question, whether it is desirable 
to start using prazosin on a large scale, the more since the 
occurrence of orthostatic collapse is a potentially dangerous 
side-effect. 
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Chapter V 
DIAZOXIDE IN HYPERTENSIVE CRISIS: 
BOLUS INJECTION OR SLOW INFUSION? 
Th. Thien, F.Th.M. Huysmans and R.A.P. Koene 
Department of Internal Medicine, Division of Nephrology and 
Out-patient Clinic, Sint Radboudziekenhuis, University of 
Nijmegen, The Netherlands 
Translated from a publication in the "Nederlands Tijdschrift 
voor Geneeskunde" 125, 1823-1828 (1981) 
SUMMARY 
During hypertensive crises, the potent vasodilator, diazoxide 
(Hyperstat) allegedly is effective only after rapid intravenous 
administration (300 mg in 10-30 seconds). In seven patients 
with hypertensive crisis, the authors compared this fast method 
with slow infusion of diazoxide (15 mg per minute). Bolus in­
jection resulted in a maximal fall of the mean arterial blood 
pressure (ΔΜΑΡ) amounting to - 31 + 11% in an average of 4 
minutes. The infusion method gave a maximal ΔΜΑΡ amounting to 
-25 + 7% after an average of 26 minutes. From the 30th minute 
after the start of the treatment, the antihypertensive effect 
was the same for both methods. Repeated infusions, and infusions 
at a lower rate (7.5 mg per minute) were also effective. Thus, 
although the two methods have the same hypotensive effect, slow 
infusion is to be preferred because it induces a gradual de­
crease of the blood pressure and can be discontinued in case of 
an excessive fall of the pressure. 
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INTRODUCTION 
Some years ago we have reported in this journal on the treat-
ment of hypertensive crisis with the potent vasodilator dia-
zoxide (Hyperstat) (1). At that time we always administered 
this drug as a bolus injection: 300 mg diazoxide intravenously 
within 10 to 30 seconds (2). Although the initial fall in blood 
pressure after such an injection is very rapid and unpredictable, 
we did not observe serious complications in 30 patients with a 
hypertensive crisis treated in this way. However, serious com-
plications such as myocardial ischaemia, anginal complaints and 
even myocardial infarction after bolus injections of diazoxide 
have now been reported, especially in those patients treated 
concomitantly with other antihypertensive agents (3-10). Al-
together 40 patients with such complications, of whom five died, 
have been reported until now to the manufacturer (11). In 
addition, neurological complications (coma, convulsions, blind-
ness, hemiparesis), ascribed to the rapid and exaggerated fall 
in blood pressure after the administration of diazoxide as a 
bolus injection (12,13), have been recently reported. There-
fore, it seems safer to aim at a more gradual decrease of blood 
pressure. 
Slow administration of diazoxide is allegedly effective in pa-
tients with stable hypertension (14,15,16), but not in patients 
with a hypertensive crisis (17). This supposed difference in 
effectiveness was explained by the strong binding of diazoxide 
to albumin (18). This binding amounts to over 90% and the 
albumin-diazoxide complex is not effective. It was presumed 
that in the less severe types of hypertension the remaining 10% 
of free diazoxide would induce sufficient vasodilation, but in 
the hypertensive crisis, which is accompanied by a very strong 
vasoconstriction, this amount would not be effective. By using 
a bolus injection one would accomplish that a higher percentage 
of free diazoxide reaches the receptors before being inactivated 
by binding to albumin. Meanwhile, a good antihypertensive effect 
had also been described of repeated bolus injections of small 
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doses of diazoxide, e.g. 50 to 150 mg at a time (11,19,20). 
These data prompted us to investigate the effect of slow infu-
sion of diazoxide. This method proved to be effective in pa-
tients with severe hypertension as well as in patients with a 
hypertensive crisis (21). 
In a small group of seven patients with hypertensive crisis we 
were able to compare the antihypertensive effect of slowly ad-
ministered diazoxide with that of a bolus injection of diazoxide 
in comparable dosages. These observations are the basis of this 
report. 
PATIENTS AND METHODS 
Table 1 shows the clinical data of the seven patients with a 
hypertensive crisis diagnosed according to the criteria of 
Kaplan (22). The patients C, D, and G showed signs of hyper-
tensive encephalopathy (vomiting, restlessness, convulsions, 
etc.). Four patients used already other antihypertensive drugs. 
Blood pressures were measured with an Erkameter 300 after ad-
mission into the hospital and with an Arteriosonde 1217 during 
the study, on the right arm, the patient being in supine po-
sition in a quiet room. A catheter was introduced in an ante-
cubital vein of the left arm for blood sampling and for the 
administration of diazoxide. Thereafter, blood pressure was 
measured every two minutes during at least half an hour. After 
stabilization of the blood pressure, administration of dia-
zoxide was started with a Braun infusion pump (type 1850). The 
infusion rate was 15 mg/min. The total dose administered 
amounted 5 mg/kg body weight, the infusion time thus being 20 
to 30 minutes. As a bolus injection 300 mg was administered 
within 10 seconds in all instances. 
The pretreatment blood pressure value was calculated as the 
mean of the last five blood pressures recorded before the dia-
zoxide administration. To be able to make a comparison with 
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Table 1. Clinical data of seven patients with a hypertensive crisis in whom the antihypertensive effect of slow 
infusion of diazoxide was compared with that of a bolus injection 
Patient, sex Cause of 
and age (years) hypertension 
Pretreatment Serum creatinine Retinopathy Left ventricular Therapy on 
blood pressure level (yraol/l) 
(mmHg)* 
(grade)1 hypertrophy admission 
A, m, 52 
B, m, 46 
renovascular 
essential 
245/142 
250/154 
88 
720 
C, f, 34 
D, f, 27 
E, m, 41 
F, m, 28 
G, m, 46 
scleroderma 
prae-eclamps ia 
essential 
glomerulonephritis 
280/160 
190/140 
290/190 
243/152 
glomerulonephritis 245/150 
(Wegener's granulomatosis) 
372 
83 
164 
1632 
210 
IV 
III 
III 
n.d. 
Ill 
IV 
II 
+ 
+ 
+ 
-
+ 
+ 
+ / -
propranolol, 
α-methyIdopa, 
hydralazine, 
furosemide 
hydralazine, 
propranolol, 
chlorthalidone 
diazepam 
triamterene, 
epithiazide, 
a-methyldopa 
propranolol 
guanidinesulphate 
prednisone, 
cyclophosphamide 
# Erkameter 300, mean of at least three measurements 
** According to the criteria of Keith et al (23); n.d. = not done 
*** According to the ECG-criteria of Romhilt and Estes (24) 
the blood pressure decrease after the bolus injection, that 
was always maximal within five minutes, the means of the blood 
pressures recorded four and six minutes after the start of the 
diazoxide infusions were calculated. Both after the infusion 
and after the bolus injection the lowest blood pressure recor­
ded and the time of this recording were noted. Besides this, 
the means of three blood pressure measurements at 30 and 60 
minutes after the start of the diazoxide were calculated. 
The MAP (mean arterial pressure) was calculated as the sum of 
the diastolic blood pressure and one third of the pulse pressure. 
If the decrease of MAP after 60 min was less than 10%, a patient 
was considered to be a non-responder. Statistical comparisons 
were made with Student's t-test for paired and unpaired obser­
vations . 
2 0 4 0 
time (minutes) 
60 
decrease О 
systolic 
blood 
pressure - 2 0 ( mm Hg) 
- 4 0 -
-60-1 
O n decrease 
diastolic 
blood 
pressure - 2 0 (mm Hg) 
- 4 0 
- 6 0 
bolus 
injection 
Figure 1. Patient A. Blood pressure decrease after bolus injection (open 
circles) and after slow intravenous infusion (15 mg/min; closed 
circles) of 300 mg diazoxide, administered with an interval of 
four weeks. 
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RESULTS 
Patient A was admitted twice with a hypertensive crisis. The 
first time (blood pressure 203/131 mmHg) he was treated with a 
bolus injection. One week thereafter he refused further treat­
ment and left the hospital without medication. Three weeks 
later he was again admitted (blood pressure 202/138 mmHg) and 
treated with an infusion (fig. 1). The bolus injection induced 
a large and rapid decrease of the systolic and diastolic blood 
pressure within the first minutes but from 20 minutes after 
the start of the treatment no difference existed between the 
blood pressures after the bolus injection and after the infusion. 
The dose of diazoxide was the same in both instances. Also, the 
long-term effect of diazoxide (decrease of MAP after eight 
hours) hardly differed: -16% after the bolus injection and -20% 
after the infusion. 
Table 2 shows the percentual decrease of the MAP in the seven 
patients at different intervals after the bolus injection and 
the slow infusion. The mean maximal decrease after the bolus 
injection was 30.9% (range 16 to 40%) after a mean time of four 
minutes. The maximal decrease after the infusion was 25.0% 
Table 2. Percentual decrease of mean arterial pressure (MAP) in seven 
patients after a bolus injection and after slow infusion of 
diazoxide 
Time after the start 
of treatment (min) 
Decrease of MAP (%) (mean + S.D.) 
After bolus 
injection 
After slow 
infusion 
9.3 + 3.2 
25.0 + 6.7 
21.0 + 7.4 
18.9 + 11.8 
Ρ-value 
<0.002 
<0.05 
n.s. 
n.s. 
4-6 
25 
30 
60 
30.9 + 10.7 
18.2 + 6.1 
17.3 + 7.4 
17.6 + 10.1 
not significant 
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(range 14 to 29%) . From 30 minutes after the start of the 
treatment the blood pressure lowering effect of both methods 
was equal. Patient С showed no response both after the infusion 
(decrease of MAP after 60 minutes: -7.1%) and after three sub­
sequent bolus injections (-8.6%) and patient F showed no res­
ponse after the bolus injection (-5.0%). 
Application of the infusion method in two other patients showed 
that a second infusion may still induce a clearcut decrease of 
blood pressure (fig. 2) and that infusion at a lower rate (7.5 
mg/min) may also be effective (fig. 3). In two of the seven 
patients the bolus injection was given first while five re­
ceived the infusion as the first treatment. The time interval 
between the use of the two treatments was four weeks in one 
patient, one day in two patients and three to four hours in 
four patients. In all patients the indication for repeated 
treatment was a rise in blood pressure or an unsatisfactory 
response after the first treatment. 
Because of the supposed influence of the protein binding of 
diazoxide on its effect we measured the total serum protein 
content. The mean value in the seven patients amounted 72.3 + 
7.8 g/1 (normal value 65-85 g/1). Both methods of administration 
induced few side-effects. In all instances an increase in pulse 
rate without subjective complaints was observed. The complaint 
of heat sensation, sometimes mentioned by the patients after a 
bolus injection, did not occur after infusion of diazoxide. 
DISCUSSION 
The results of our study show, that slow infusion of diazoxide 
is as effective as a bolus injection in the treatment of hyper­
tensive crisis. This is in contrast with earlier data from the 
literature (17). The effectiveness of the infusion in our 
patients cannot be explained by a lower serum protein content, 
that would allow more free diazoxide to reach the receptors, 
since their serum protein levels were normal. Besides the serum 
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Figure 2. A patient with a hypertensive crisis (convulsions) received 
diazoxide by intravenous infusion twice, because the convulsions 
remained after the first infusion despite a satisfactory decrease 
of blood pressure (ΔΜΑΡ -18.0%). After the second infusion (ΔΜΑΡ 
-17.9%) convulsions disappeared and consciousness was gained. 
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Figure 3. A patient with severe prae-eclampsia received 300 mg diazoxide by 
intravenous infusion at half the normally used infusion rate 
(7.5 instead of 15 mg/min) because of the expected greater 
sensitivity (25). 
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protein content, renal function probably also plays a role in 
the protein binding of diazoxide. Pearson and Breckenridge (26) 
demonstrated that the protein binding of diazoxide was very low 
in patients on chronic haemodialysis, whereas the serum albumin 
levels were only slightly decreased in these patients. In 
another group of patients they also found a clearcut relation 
between the maximal decrease of blood pressure after a bolus 
injection and the plasma urea level. In five of our seven 
patients the favourable reaction on the infusion of diazoxide 
could have been related to a decreased renal function, although 
in the two patients with normal function the decreases of blood 
pressure after bolus injection and infusion were also the same. 
Moreover, we did not find a relation between renal function and 
the maximal decrease of blood pressure after diazoxide infusion 
in a larger group of 81 patients. 
Because of the complications of bolus injections of diazoxide 
mentioned in the introduction, slow infusion accompanied by a 
gradual decrease of blood pressure represents an important im-
provement in the treatment of hypertensive crisis. Moreover, 
infusion offers the opportunity to discontinue the administra-
tion if blood pressure has sufficiently decreased. For this 
study we chose a fixed infusion rate, but one observation (fig. 
3) shows that the infusion rate may be halved without problems. 
From a pharmacokinetic point of view it is indeed not surpri-
sing that an agent with a half-life time of 20 to 53 hours (27) 
can also be effective if the same dose is administered slowly. 
Also the favourable experience with oral administration of 
diazoxide in the chronic treatment of hypertension (28,29) is 
an argument against the concept that diazoxide is inactivated 
by its strong protein binding. 
Slow administration of diazoxide is especially useful in 
patients with coronary insufficiency or in patients in whom the 
decrease of blood pressure is exaggerated because of an in-
sufficient compensatory rise of cardiac output (30). Slow ad-
ministration is also important in patients in whom acute treat-
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ment is necessary despite an only moderate deviation of the pre-
treatment blood pressure (hypertensive encephalopathy, eclamp-
sia) and in patients in whom an increased sensitivity can be 
expected (decreased serum protein level, renal insufficiency, 
preceding treatment with diuretics). 
Neurological complications after a bolus injection have only 
been described in patients, in whom the fall in blood pressure 
was very large (a decrease of MAP of 50 to 70%) (13). In the 
30 patients whom we have treated with a bolus injection of dia-
zoxide, the maximal decrease was never larger than 50% and 
only in a few instances larger than 40%. This may explain the 
fact that we have never observed neurological complications in 
our patients. Assuming that the cerebral autoregulation may be 
jeopardized after a rapid blood pressure reduction of more than 
25% (31), it seems wise to abandon the application of the bolus 
injection as a routine procedure. The mean maximal decrease of 
blood pressure after the bolus injection in the seven patients 
described here, amounted 30.9%.(range 16-40%). After slow in-
fusion these patients showed a mean maximal decrease of blood 
pressure of 25.0% (range 14-29%) and thus the limit of 25%, 
mentioned in the literature was hardly exceeded. Moreover, the 
decrease of blood pressure occurred much more gradually. 
In some recent editorials (32,33) the danger of the rapid and 
large fall in blood pressure after a bolus injection of diazoxide 
has been stressed. In these editorials also attention has been 
paid to the fact, that only in a few cases a very rapid reduc-
tion of blood pressure is required and that a more gradual re-
duction of blood pressure in several hours is almost always 
acceptable without the need to aim at a completely normal blood 
pressure level. Only in patients with signs of hypertensive en-
cephalopathy with or without coma, with an epileptic state, or 
with an acute left-sided heart failure caused by hypertension, 
prompt treatment is required. 
Because of the reported complications of the bolus injection of 
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diazoxide and since we could demonstrate that the blood pressure 
is equally well reduced by slow infusion, we prefer this latter 
method of administration. Meanwhile we have used the infusion 
method at more than 100 occasions without the occurrence of any 
neurological or cardiac complications. 
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Chapter VI 
ACUTE TREATMENT OF HYPERTENSION WITH 
SLOW INFUSION OF DIAZOXIDE 
F.Th.M. Huysmans, Th. Thien and R.A.P. Koene 
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Out-patient Clinic, Sint Radboudziekenhuis, University of 
Nijmegen, The Netherlands 
SUMMARY 
We have treated 81 hypertensive patients with slow i.v. infusion 
of diazoxide (15 mg/min, 5 mg/kg body weight). Blood pressure 
was reduced effectively both in patients with severe hyperten­
sion (n=40) and in those with a hypertensive crisis (n=34), 
the decrease of mean arterial pressure (ΔΜΑΡ) being -17.0 +1.2% 
(mean + SEM) and -19.7 + 1.5% respectively. However, ΔΜΑΡ was 
significantly larger in (pre)eclamptic patients (-26.0 + 3.0%) . 
In all instances blood pressure fell gradually and hardly de­
creased further after discontinuation of the infusion. Thus, 
the potentially hazardous, steep and exaggerated fall of blood 
pressure, observed after bolus injections, can be avoided. In 
two patients ECG-signs of myocardial ischemia were seen. No 
other serious side-effects were observed. We conclude that, 
even in patients with a hypertensive crisis, slow infusion is 
a safe and effective procedure for reduction of blood pressure. 
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INTRODUCTION 
In recent years several vasodilators have been recommended for 
the treatment of hypertensive emergencies, especially diazoxide 
because of its prompt and long lasting effect (1). However, 
serious complications of the use of diazoxide have been repor-
ted which were related to the sudden and large fall of blood 
pressure (2-4). This steep fall of blood pressure was a conse-
quence of the fact, that diazoxide was administered as an in-
travenous bolus injection, because it was thought that slow 
administration was not effective in patients with a hyperten-
sive crisis (5). 
It was assumed that the ineffectiveness of diazoxide after 
slow infusion was caused by its binding to serum albumin, thus 
forming a supposedly inactive complex (6). The state of genera-
lized vasoconstriction in this condition would require large 
amounts of unbound diazoxide at the vascular receptor site 
which would only be achieved by rapid i'njection. When we re-
evaluated this problem in a small number of patients with a 
hypertensive crisis we found that the infusion method was as 
effective as the bolus injection (7). We have now extended our 
experience with administration of diazoxide by infusion to a 
total number of 81 patients. We report here that it is equally 
effective in patients with a hypertensive crisis and in those 
with severe hypertension, whereas patients with (pre)eclampsia 
show increased sensitivity. The infusion induced a smooth de-
cline of blood pressure and serious complications did not occur. 
PATIENTS AND METHODS 
The clinical data of 81 patients with hypertension are summa-
rized in Table 1. Fifteen patients had end-stage renal failure 
and were on chronic hemodialysis. Thirty four patients had a 
hypertensive crisis defined as a diastolic blood pressure of 
over 130 mmHg with a hypertensive retinopathy grade III or IV 
(9), or a diastolic blood pressure of over 100 mmHg with clear 
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Table 1. Clinical data of Θ1 patients 
Mean age (years)* 40.2 +1.5 (15-64) 
Sex (male/female) 45/36 
Cause of hypertension 
essential 35 
nephrogenic 26 
renovascular 10 
eclamptic 7 
other 3 
Left ventricular hypertrophy** 46 
Retinopathy*** 
grade 0 23 
grade I-II 31 
grade III-IV 27 
Endogenous creatinine clearance 
more than 100 ml/min 13 
50-100 ml/min 33 
5-50 ml/min 20 
l e s s than 5 ml/min 15 
* Mean value +_ S.E.M., range in p a r e n t h e s i s 
* * According t o t h e ECG-criteria of Romhilt and Estes (8) 
* * * According t o the c r i t e r i a of Keith, Wagener and Barker (9) 
signs of a hypertensive encephalopathy. Forty p a t i e n t s had 
severe hypertension defined as a d i a s t o l i c blood pressure of 
over 120 mitiHg without these symptoms, measured on a t l e a s t three 
consecutive occasions. Seven pregnant p a t i e n t s had (pre)eclamp­
s i a which was defined according to Chesley (10). Thirty four 
of the 74 non-eclamptic p a t i e n t s had not received any ant ihyper­
tens ive drug in the l a s t two weeks before the study. 
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The patients were treated with diazoxide, infused intravenous-
ly at a rate of 15 mg/min, in a total dose of 5 mg/kg body 
weight with a minimal dose of 300 mg. The infusion time thus 
varied from 20 to 30 min. In three patients the infusion was 
discontinued shortly before the full dose had been given 
because there was a satisfactory decrease of blood pressure. 
From 30 min before to 60 min after the start of the infusion 
the patients were in the recumbent position. During this period 
their blood pressures were recorded every two min with an auto-
matic device (Arteriosonde 1217). Seven hours later blood 
pressure was again recorded after 30 min rest in supine posi-
tion in 17 patients, who had not received further therapy 
during this period. In 55 patients an electrocardiogram was 
made immediately before and at 30 and 60 min after the start of 
the infusion. From these recordings heart rates were calculated. 
Blood samples were drawn immediately before and 60 min after 
the start of the infusion for the determination of plasma or 
serum levels of creatinine (n=56), urea (n=47), urate (n=43), 
glucose (n=64), triglycerides (n=7), free fatty acids (n=13), 
insulin (n=12), and renin activity (PRA, n=35). In the first 
serum sample levels of total protein (n=72) and albumin (n=69) 
Were also determined. 
Blood pressure values given are the means of five consecutive 
readings immediately before, of two at 5 min, and of three 
consecutive readings at 30 and 60 min after the start of the 
diazoxide infusion. Mean arterial pressure (MAP) was calcula-
ted as the sum of the diastolic blood pressure and one third 
of the pulse pressure. All values given are means + S.E.M. 
Statistical analysis was performed with Student's t-test for 
paired and unpaired observations. Correlations were calculated 
according to Pearson. A P-value of 0.05 was considered as the 
level of statistical significance. 
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RESULTS 
The effect of diazoxide infusion on blood pressure in all 81 
patients is given in Fig. 1. Blood pressure fell gradually, the 
decrease of MAP being only 5.7 + 0.5% five min after the start 
of the infusion. The effect of diazoxide on blood pressure was 
maximal at 26.7 + 0.5 min after the start of the infusion with 
a decrease of MAP of 25.3 + 1.0%, whereas the mean infusion 
time amounted to 23.1 + 0.4 min. The mean maximal decrease of 
MAP after discontinuation of the infusion was 2.8 + 0.5%, demon­
strating that there was virtually no further fall in blood 
pressure. The maximal further decrease observed was 21 mmHg for 
the systolic pressure and 16 mmHg for the diastolic pressure. 
In the 17 patients in whom blood pressure was recorded seven 
hours later, MAP was still 15.0 + 2.7% below the pretreatment 
level, whereas it had decreased initially by 20.0 + 2.0% in 
these patients. Table 2 shows that the decrease of MAP was 
comparable in patients with severe hypertension and hyperten-
Blood pressure (mmHg) 1 
200-
160 
120 
80 
-5.7 .25.3.21.1 .18.8 ΔΜΑΡ(%| 
( ' 1 1 1 
0 30 60 
Time (min) 
Figure 1. Blood pressures and percentual decreases of mean arterial pressures 
(MAP) after the start of the diazoxide infusion. The maximal 
effect of the infusion was attained after a mean infusion time of 
27 min (see text). 
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T a b l e 2 . Blood p r e s s u r e r e s p o n s e t o d i a z o x i d e i n f u s i o n a t 60 min and 
serum p r o t e i n l e v e l s 
H y p e r t e n s i v e ( P r e ) e c l a m p s i a S e v e r e 
c r i s i s h y p e r t e n s i o n 
No. of p a t i e n t s 34 7 40 
I n i t i a l b l o o d 201 + 5/133 + 3 172 + 6/127 + 11 174 + 4/116 + 2 
p r e s s u r e (mmHg) 
Δ MAP (%)* - 1 9 . 7 + 1.5 - 2 6 . 0 + 3 . 0 - 1 7 . 0 + 1.2 
- L I - 1 I 
Ρ < 0 . 0 5 Ρ < 0 . 0 0 5 
T o t a l serum 6 9 . 0 + 1.4 5 6 . θ + 2 . 9 7 0 . 1 + 1.1 
. - I 1 - L — I 
p r o t e i n ( g / D * Ρ <0.001 Ρ <0.0001 
*Mean v a l u e s + SEM 
sive c r i s i s , but s i g n i f i c a n t l y la rger in (pre)eclamptic p a t i e n t s . 
In t h i s l a t t e r group, t o t a l serum p r o t e i n leve l s were s i g n i f i ­
cant ly lower. To find out whether t h i s fac tor played a r o l e in 
the blood pressure response to diazoxide we compared p a t i e n t s 
without (pre)eclampsia with serum p r o t e i n leve l s above 75 g/1 
(n=17) and below 65 g/1 (n=l8). The decreases of MAP in these 
two groups did not d i f fe r s i g n i f i c a n t l y , being 18.6 + 2.3% and 
22.0 + 2.3% r e s p e c t i v e l y . The same held t rue when we compared 
non-(pre)eclamptic p a t i e n t s with a serum albumin above 50 g/1 
(n=18) and below 40 g/1 (n=18) (16.6 + 1.9% and 21.0 + 2.1% 
r e s p e c t i v e l y ) . However, in the whole group of p a t i e n t s without 
(pre)eclampsia a weak, but s i g n i f i c a n t c o r r e l a t i o n ex i s ted 
between the decrease of MAP on the one hand and serum p r o t e i n 
leve l s (r=0.27, n=66, p<0.05) and serum albumin l e v e l s (r=0.24, 
n=66, p<0.05) on the o t h e r . The di f ferences in sex may a l so 
have played a r o l e in the larger blood pressure response of the 
(pre)eclamptic p a t i e n t s , s ince we found t h a t the decrease of 
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MAP in females without (pre)eclampsia (n=29) was significantly 
greater than in males (n=45) (21.3 + 1.5% and 16.3 + 1.2%, res­
pectively) , whereas serum protein and albumin levels did not 
differ. Of no other factor we could find an influence on the 
blood pressure response to diazoxide. No correlation existed 
between the decrease of MAP on the one hand and age, body weight, 
endogenous creatinine clearance, serum urea or pretreatment 
levels of MAP, on the other hand. The decrease of MAP in the 
patients who had not received any antihypertensive drug in the 
last two weeks before the study was not different from that in 
previously treated patients (16.6 + 1.4% and 19.8 + 1.2% res­
pectively) . Nine patients showed no clear response to diazoxide 
(decrease of MAP less than 10%). Five of these non-responders 
had a hypertensive crisis. Heart rate rose from 80.4 + 2.2 to 
9 8.1 + 2.4 beats/min at 30 min after the start of the diazoxide 
infusion while it was 97.1 + 2.3 beats/min at 60 min. PRA rose 
by 38.5 + 9.0% (n=35). However, we found no correlation between 
the changes in these two parameters and the decreases of MAP. 
The serum level of creatinine rose from 176.1 + 21.3 to 195.6 + 
21.9 pmol/l (p<0.001), that of urea from 10.80 + 1.26 to 11.64 
+ 1.24 mmol/1 (p<0.05) and that of urate from 0.433 + 0.021 to 
0.477 + 0.024 mmol/1 (p<0.005), but again there was no signifi­
cant correlation with the decrease of MAP. Serum levels of 
patients on hemodialysis were excluded from these calculations. 
As expected, blood glucose levels rose significantly from 6.00 
+0.16 mmol/1 to 7.30 + 0.25 mmol/1. In only three patients 
blood glucose levels increased above 10 mmol/1, the maximal 
level being 16.0 mmol/1. These rises in glucose were accompa­
nied by a decrease of plasma insulin levels from 28.92 + 5.25 
u
U/ml to 14.08 + 2.67 yU/ml and by an increase of the level of 
free fatty acids in the plasma from 0.353 + 0.051 μΜ/l to 1.250 
+ 0.209 μΜ/l. The serum levels of triglycerides did not change. 
In only two of the 55 patients in whom an electrocardiogram was 
made before and after the procedure, we observed electrocardio­
graphic signs of increased myocardial ischemia consisting of a 
depression of the ST-segment of more than one mm. None of the 
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patients had anginal complaints during or after the infusion. 
No other serious side-effects were observed. 
DISCUSSION 
In contrast to the current opinion according to which diazoxide 
has to be given as a bolus injection in patients with a hyper-
tensive crisis (5), slow infusion of diazoxide appeared to 
lower blood pressure effectively in such patients as well as 
in those with severe hypertension. Blood pressure decreased 
gradually and smoothly, so that unexpected and sudden falls in 
pressure did not occur. The infusion period of 20 to 30 min 
provided time to evaluate the individual reaction of the patient 
and to interrupt the administration in those patients who 
showed increased sensitivity to the drug. We have preliminary 
evidence that even slower infusion rates, than used in this 
study, can be effective. After discontinuation of the infusion 
the further decrease of the blood pressure was negligible. Thus, 
the exaggerated fall of blood pressure that is often observed 
within five min after a bolus injection of diazoxide (1) could 
be completely avoided. This steep decline is probably the cause 
of the reported myocardial ischemia and infarctions, and of the 
irreversible neurological complications after bolus injections 
of diazoxide (2,3,4). Therefore, it is likely that the incidence 
of serious side-effects can be diminished by administering 
diazoxide as a slow infusion instead. 
Diazoxide appeared to be more effective in patients with (pre)-
eclampsia. Since these patients have decreased serum protein 
and albumin levels (11) and since the absence of effectiveness 
of diazoxide in a hypertensive crisis has been attributed to 
the strong binding of this drug to albumin (6) we compared the 
blood pressure lowering effect of diazoxide in patients without 
(pre)eclampsia with high and low levels of serum protein. Al-
though we did not find significant differences, the correlation 
in the whole group between serum protein and albumin levels and 
blood pressure decreases after diazoxide nevertheless suggested 
79 
that the albumin binding of the drug may have some influence. 
The decrease of blood pressure after diazoxide administration 
was not larger in patients with decreased renal function, al-
though the binding of diazoxide to albumin or protein is lower 
in patients with uremia (12). All these findings suggest that 
differences in protein binding are of minor importance for the 
antihypertensive effect of diazoxide. Meanwhile, it remains 
unexplained why patients with (pre)eclampsia are so sensitive 
to the drug. 
Although one would have expected that older patients are more 
sensitive to diazoxide because their baroreceptor reflex arch 
functions less efficiently (13), we found no influence of age. 
Similarly we found no increased sensitivity in patients who 
already used other antihypertensive drugs, although synergism 
between these drugs and diazoxide might have been expected on 
theoretical grounds. Thus, only in patients with (pre)eclampsia, 
one should reckon with an increased responsiveness to diazoxide. 
In such patients slow infusion instead of a bolus injection of 
diazoxide is especially indicated. For obvious reasons this 
special indication also holds for patients with insufficient 
coronary or cerebral circulation. Although multiple small i.v. 
bolus injections can also reduce blood pressure effectively 
(14), slow infusion seems to be a more practical approach. If 
the blood pressure reduction after diazoxide administration is 
insufficient, as was the case in five of our patients with a 
hypertensive crisis, a second infusion can be successful. 
As could have been expected after direct vasodilation, heart 
rate and plasma renin activity rose after diazoxide administra-
tion (15). Apart from the blood pressure reduction per se, this 
compensatory rise in heart rate has probably also played a role 
in the occurrence of myocardial ischemia and infarctions, ob-
served after bolus injections of diazoxide (2). Although we 
have observed slight ECG-signs of myocardial ischemia in only 
two of 55 patients in whom an ECG before and after infusion 
was made, it seems nevertheless preferable to try to prevent 
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the compensatory tachycardia under all circumstances. We have 
reported elsewhere (16) that this goal can be readily achieved 
by the intravenous injection of a beta-blocking agent prior to 
the infusion of diazoxide. While such a procedure prevents the 
tachycardia, it does not increase the antihypertensive effect 
of diazoxide. 
The observed rises of plasma creatinine, urea, and urate levels 
after vasodilation with diazoxide are not unexpected (17). The 
changes were only small and did not correlate with the changes 
in blood pressure which is not surprising since blood samples 
were taken already one hr after the start of diazoxide infusion. 
Yet, we ascribe these rises to the decrease of blood pressure, 
since we have found a significant correlation between these 
parameters during chronic treatment with diazoxide (IB). The 
decrease of renal function is probably a consequence of a de-
crease of renal perfusion during blood pressure reduction. 
The diabetogenic effect of diazoxide (19) never posed a problem 
during this short term use. We saw only small rises of plasma 
glucose levels, which were accompanied by a decrease of plasma 
insulin levels. These findings are in accordance with experi-
mental studies in which it was shown that diazoxide suppresses 
the secretion of insulin directly in the pancreas (20). Other, 
especially adrenergic mechanisms might have contributed to the 
rise of plasma glucose levels (21). The decrease of insulin 
secretion also induced, as expected (22), a rise of free fatty 
acids. A reflex adrenergic mechanism may also have played a 
role in this increase (21). Since the period of treatment was 
very short, changes in serum triglyceride levels, that occur 
during chronic inhibition of insulin secretion (23), were not 
observed in this study. 
We conclude that with slow infusion of diazoxide one can 
achieve a smooth reduction of blood pressure in most hyperten-
sive patients including those with a hypertensive crisis. A 
greater blood pressure response to diazoxide can be expected 
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in patients with (pre)eclampsia. The rises of heart rate, plasma 
renin activity and of creatinine, urea and urate levels, are in 
keeping with the concept that diazoxide exerts its antihyper-
tensive effect by direct vasodilation. We observed no serious 
side-effects. Infusion of diazoxide is therefore a better pro-
cedure for the acute treatment of hypertension than the common-
ly used bolus injection. 
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Chapter VII 
COMBINED INTRAVENOUS ADMINISTRATION OF DIAZOXIDE AND 
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Nijmegen, The Netherlands 
American Heart Journal, vol. 103, no. 3, pp. 395-400 (1982) 

Combined intravenous administration of 
diazoxide and beta-blocking agent in acute 
treatment of severe hypertension or 
hypertensive crisis 
Twenty-nine patients with severe hypertension (n = 14) or hypertensive crisis (n = 15) were 
treated with diazoxide Infusion and intravenous injection of a beta blocker. In 13 patients 
diazoxide was administered first. It gradually reduced mean arterial pressure (MAP) by 
16.1 ± 2.1% (mean ± SEM), and Increased heart rate (HR) by 27.3 + 4.1% and plasma renin 
activity (PRA) by 48.9 ± 13.0%. Beta blockade thereafter lowered MAP by only 1.2 ± 1.9% 
despite reductions of HR by 25.6 : 2.2% and of PRA by 17.1 ± 5.9%. In 16 other patients a beta 
blocker, when given first, reduced MAP by 3.5 + 1.2%, HR by 18.9 ± 1.8%, and PRA by 
24.4 + 4.4%. Diazoxide Infusion thereafter gradually reduced MAP further by 21.9 ± 1.9% and 
raised HR and PRA to pretreatment levels. No complications were observed. Beta blockade 
before diazoxide Infusion effectively prevents a rise In HR above control levels while its acute 
effect on blood pressure is negligible. It Is advisable to use this combined treatment in all 
situations where the occurrence of tachycardia might be dangerous. (AM HEART J 103.395, 1982.) 
Frans Th.M. Huysmans, M.D., Theo A. Thien, M.D., and Robert A. P. Koene, M.D. 
Nijmegen, The Netherlands 
Intravenous administration of diazoxide is a fre­
quently used treatment for patients with hyperten­
sive crisis. On the basis of earlier studies it has been 
regarded necessary to administer this drug by bolus 
injection, since slow administration was supposed to 
decrease blood pressure (BP) in this condition insuf­
ficiently.' However, rapid diazoxide injection may 
cause large initial fall in BP which sometimes leads 
to anginal pain, myocardial infarction, or neurologi­
cal complications.2 6 Because of these serious compli­
cations some clinicians have recommended using 
multiple intravenous injections of lower doses.7 9 In a 
previous study10 we found that, unlike earlier find­
ings of others, slow intravenous infusion of diazoxide 
is as effective as bolus injection in the treatment of 
hypertensive crisis. This slower method is much 
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safer since the unpredictable and often exaggerated 
BP decline is avoided. Moreover, when the infusion 
is discontinued and BP has decreased sufficiently, 
there is no further fall in BP. 
However, even such gradual and controlled 
decrease of BP might still induce myocardial 
ischemia, since infusion of diazoxide is accompanied 
by increased heart rate (HR) comparable to that 
observed after bolus injection." This fact may be of 
substantive importance since HR is already elevated 
in many untreated hypertensive patients.12 Thus 
diazoxide might be especially harmful in patients 
with acute myocardial infarction or dissecting aortic 
aneurysm, where tachycardia may aggravate either 
condition.13 " A possible approach to circumvent 
this problem is to lower HR by combining diazoxide 
with a beta-adrenoceptor blocking agent. On the 
other hand, diazoxide-effected vasodilator BP low­
ering is counteracted by reflex increased HR and 
plasma renin activity (PRA),15 the suppression of 
which by beta-adrenergic blockade might lead to 
further undesirable BP decline. 
Preliminary studies have suggested that this drug 
combination may not be hazardous, since Man in 't 
Veld et al.16 and Mroczek et al." did not find an 
increase in the antihypertensive effect of diazoxide 
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Fig. 1. Effects of diazoxide infusion and subsequent 
intravenous injection of a beta blocker on blood pressure, 
heart rate, and plasma renin activity (PRA) in group A 
patients (n = 13). The duration of the diazoxide infusion 
varied between 20 and 30 minutes. 
after propranolol administration. However, since 
propranolol was only given before diazoxide injec­
tion in both studies,16· " the precise contribution of 
beta blockade to the antihypertensive effect of this 
drug combination was not fully clarified. To further 
evaluate this therapeutic approach, we studied the 
effects of beta-adrenoceptor blocking agents, 
administered intravenously either immediately 
before or after diazoxide infusion. Our results show 
;hat despite marked reductions in HR and moderate 
group A group В 
Number 
Age (years)* 
Male/female 
Severe hypertension 
Hypertensive crisis 
Nature of hypertension 
Essential 
Nephrogenic 
Renovascular 
Other 
Endogenous creatinine 
clearance* (ml/min) 
Organ damage 
LVHt 
Retinopathy1' 
0 
I I I 
I1I-IV 
13 
44.2 
9/4 
9 
4 
5 
4 
I 
3 
62.5 
4 
5 
7 
1 
±4.4 
± 9 . 1 
16 
39.8 ± 3.3 
7/9 
5 
11 
7 
9 
0 
0 
54.4 ± 8.1 
H 
3 
6 
7 
•Mean ± SEM. 
tLeft ventricular hypertrophy (LVH) by ECG criteria." 
decreases of PRA, such combined treatment causes 
only slight decrease of systolic BP without relevant 
change of diastolic BP. 
METHODS 
Patients. Twenty-nine patients with severe hyperten­
sion or a hypertensive crisis were studied. Severe hyper­
tension was defined as diastolic BP > 120 mm Hg meas­
ured by forearm-cuff mercury sphygmomanometer (Erka-
meter 300) on at least three occasions in the outpatient 
clinic. Hypertensive crisis was defined as diastolic BP 
> 130 mm HG combined with retinopathy grade III or 
IV," or diastolic BP > 100 mm Hg combined with mani­
festations of hypertensive encephalopathy. The patients 
had not used any antihypertensive agent in the last 2 
weeks before study. 
Study protocol. Thirteen patients were treated with 
intravenous infusion of diazoxide (group A). Ninety min­
utes after the start of this infusion, a beta-adrenoceptor 
blocking agent was slowly injected intravenously. In the 16 
other patients (group B), a beta-adrenoceptor blocker was 
administered intravenously as the first drug. Sixty min­
utes after this injection, the diazoxide infusion was 
started. The infusion rate of diazoxide was 15 mg/min to a 
total dose of 5 mgAg body weight with the minimum dose 
being 300 mg. The infusion time varied between 20 and 30 
minutes. Propranolol (0.20 mg/kg intravenously) was used 
as the beta-adrenoceptor blocking agent in 11 patients 
(four in group A and seven in group B), while the 
remaining 18 patients received metoprolol in an equipo-
tent dose (0.25 mgAg intravenously)." Supine BP was 
measured at 2-minute intervals with an automatic device 
(Arteriosonde). The recording was started at 30 minutes 
before administration of the first drug and continued 
during 150 minutes. AU BP values given are the means of 
three consecutive readings in each patient. Mean arterial 
pressure (MAP) was calculated as the sum of diastolic BP 
and one third of the pulse pressure. HRs were recorded by 
ECG immediately before administration of each drug and 
at regular intervals thereafter. 
Data analysis. To calculate the effects of the different 
drugs we took the following reference points: immediately 
before drug administration, 60 minutes after the start of 
the diazoxide infusion, and 30 minutes after the injection 
of the beta-adrenoceptor blocker. Blood samples for PRA 
measurements were also obtained at these times. All data 
are expressed as means ± SEM. Statistical comparisons 
between the two groups were performed with Student's t 
test for unpaired observations or with the chi-square test. 
Changes in PRA were analyzed by the nonparametrical 
Wilcoxon test for paired data, and changes in BP and HR 
by Student's paired ί test. Linear correlations were deter­
mined according to Pearson. A ρ value of 0.05 was 
considered as the level of statistical significance. 
RESULTS 
Table I shows the initial clinical and laboratory 
findings of the patients comprising group A and 
group B. There were no significant diflferences 
between the two groups with respect to these vari­
ables. 
Group A effects (diazoxide plus beta blockade). 
When diazoxide was given as the first drug (group 
A), there was a gradual decrease of both systolic and 
diastolic BP with concomitant rise in HR (Fig. 1). 
The mean decrease of MAP after 60 minutes was 
16.1 ± 2.1% (Table II). Injection of the beta-adre­
noceptor blocking agent resulted in a further 
decrease of MAP of only 1.2 ± 1.9% (Table II); this 
decrease was the result of a fall of systolic BP only 
(Fig. 1). In none of the patients was the overall BP 
decline of undesirable magnitude; the greatest over­
all decrease of MAP observed in a patient was 
29.4%. While effects of the beta-adrenoceptor 
blocker on BP were minor, there was a significant 
decrease of mean HR to below pretreatment levels 
(Table II). It can be seen in Fig. 1 that the effects of 
the beta-adrenoceptor blocker were already fully 
expressed by 5 minutes after its injection. The 
product of HR and systolic BP (an indirect index of 
myocardial oxygen consumption),2 1 which had 
increased after diazoxide infusion from 13,848 to 
15,174 mm Hg · beats/min, fell sharply after beta 
blockade to 10,261 mm Hg · beats/min, a value 
significantly below the control level. The changes in 
mean PRA are also given in Fig. 1. PRA increased 
significantly after diazoxide infusion by 48.9 ± 
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Fig. 2. Effects of intravenous injection of a beta blocker 
and subsequent diazoxide infusion on blood pressure, 
heart rate, and plasma renin activity (PRA) in ^roup В 
patients (n = 16). The duration of diazoxide infusion 
varied between 20 and 30 minutes. 
13.0% and fell to levels not significantly different 
from pretreatment values after the subsequent 
administration of the beta-adrenoceptor blocker. 
Group В effects (beta blockade plus diazoxide). 
When the beta-adrenoceptor blocker was adminis­
tered as the first agent (group B), we also observed a 
significant decrease of systolic BP only (Fig. 2). The 
mean decrease of MAP after 30 minutes was 3.5 ± 
1.2% (Table II). This decrease was accompanied by 
a fall in HR and the effects were again fully 
expressed within 5 minutes after the injection, as 
Θ9 
Table II. Comparison of group A and group В responses of blood pressure and heart rate 
After diaztiude 
¿MAP ДШР· 
(%) (fi) 
' - changes in mean arterial pressure (MAP) 
ь
 = changes in heart rate (HR) 
c
 = significance of differences between groups A and В 
illustrated in Fig. 2. Subsequent infusion of diazox-
ide resulted in gradual decrease of both systolic and 
diastolic BP with concomitant rise in HR (Fig. 2). 
Also in this group exaggerated decreases of BP were 
not observed, the largest overall decrease of MAP in 
a patient being 35.4%. The rate-pressure product 
fell sharply after beta-blockade from 19,564 to 
14,621 mm Hg - beate/min, and remained signifi­
cantly below the control value after diazoxide infu­
sion at a level of 13,928 mm Hg · beats/min. PRA 
decreased significantly by 24.4 ± 4.4% after beta-
blockade and increased after diazoxide to levels that 
were not significantly different from pretreatment 
values (Fig. 2). 
Comparison of group A and group В regimens on MAP 
and HR. The responses of MAP and HR in the two 
groups are compared in Table II. The fall in MAP 
when diazoxide was given before the beta-adreno-
ceptor blocker (group A) was significantly smaller 
than in group В where diazoxide was given as the 
second drug. The reverse was true for the HR. 
However, we did not find a significant correlation 
between the diazoxide-induced changes of MAP and 
HR. The effects of the beta-adrenoceptor blocker on 
BP were not significantly different between the two 
groups, but HR decreased more in group A where 
diazoxide had been given first. We did not observe 
complications of the treatment procedures in any of 
the 29 patients. 
DISCUSSION 
Effectiveness of slow diazoxide Infusion. Slow infu­
sion of diazoxide appeared to lower BP effectively 
and safely. Until recently it was generally accepted 
that this mode of administration was ineffective in 
the treatment of hypertensive crisis. In the indivi­
duals that we studied herein, there were 15 patients 
with hypertensive crisis and their mean decrease of 
MAP was not significantly different from that in the 
remaining 14 patients with severe hypertension 
After beta-adrenoceptor blocker 
ΔΛΜΡ ДНЯ 
Ch) (%) 
4.1 -12 ± 1.9 -25.6 ± 2 2 
2 6 -3.5 ± 1.2 -18 9 ± 18 
NS < 0.05 
(21.5 ± 2.0 and 17.0 ± 2 . 1 % , respectively). This 
confirms and extends our previous observations that 
slow infusion of diazoxide is an effective means of 
lowering BP in both types of hypertension. 
Consideration of greater diazoxide BP decline with 
beta blockade pretreatment. In the patients who were 
pretreated with a beta-adrenoceptor blocker, we 
observed a somewhat greater BP decrease after 
diazoxide. This could be the consequence of the 
significantly higher BP levels before the start of 
treatment in these patients, since we found a signif­
icant, although weak correlation (r = -0.40, 
ρ < 0.05), between BP pretreatment levels and the 
reductions of BP after diazoxide infusion in all 29 
patients. Another factor might be the observation 
period after the start of beta blockade which was 90 
minutes longer in group B. The maximal hypoten­
sive effect after intravenous administration of a 
beta-adrenoceptor blocker in untreated hyperten­
sive patients is not reached until after 1 to 2 hours.22 
Therefore, the greater decrease of MAP in group В 
after diazoxide infusion may be attributed to the 
combined effect of beta blockade and diazoxide 
that, due to the shorter observation time, did not 
become apparent in group A. 
Minimal beta blockade BP decline In combination 
with diazoxide. Although not substantiated by clini­
cal studies, it has been advised to reduce the dose of 
diazoxide, when given as a bolus injection in combi­
nation with beta blockade, because of concern that 
severe hypotension might occur.23 Our results show 
that such concern is unjustified, at least when slow 
infusion of diazoxide is used. The intravenous 
administration of the beta blocker induced in both 
regimens only a slight fall of systolic BP. 
Salutary beta blockade-effected absent HR rise and 
lowered М О
г
 with diazoxide. The influence of beta-
blockade on HR was more important. In group A, 
HR increased after diazoxide from 79.2 ± 3.9 to 
maximally 102.2 ± 5.4 beats/min and subsequently 
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decreased after beta blockade to 71.2 ± 2.0 beats/ 
min. In group В the short period of elevated HR 
post-diazoxide was completely prevented, since in 
these patients HR decreased from the higher pre-
treatment level of 97.0 ± 6.2 to 91.2 ± 4.8 beats/ 
min after the administration of the two drugs. The 
changes in the rate-pressure product indicated a 
reduction of myocardial oxygen consumption 
(MV02) by beta blockade. It is likely that this effect 
should lower the hazard of myocardial ischemia, and 
therefore the use of beta blockade with diazoxide 
seems especially attractive in high-risk patients with 
angina pectoris or acute myocardial infarction.13 
Inhibition of the rise in cardiac output is probably 
also important in patients with dissecting aneurysm 
of the aorta." 
Consideration of propranolol ve metoprolol. Since 
metoprolol and propranolol do not have the same 
effect on beta2-receptors,19 differences in the hemo­
dynamic effects of these two beta blockers might 
have been expected. We did not find significant 
differences between the effects of these two drugs on 
BP or HR, but the decrease in systolic BP tended to 
be greater after metoprolol (-8.3 ± 1.8%) than 
after propranolol (—3.5 ± 1.2%). We chose relative­
ly high doses of propranolol and metoprolol in this 
study to ascertain that beta blockade during diazox­
ide was complete.17 In clinical practice lower doses 
are commonly administered which might be equally 
effective. 
Consideration of diazoxlde-induced acute PRA rise. 
The diazoxide-induced moderate rise of PRA was 
not significantly smaller in the patients who were 
pretreated with a beta blocker. The moderate 
decreases of PRA after beta blockade were also 
comparable in the two groups. Overall we observed 
no change of PRA by the combined treatment with 
both drugs. We found no correlation between 
changes of PRA with changes of BP or HR. This 
leads to the conclusion that acute changes in PRA 
levels did not play a major role in the compensatory 
changes after diazoxide infusion. 
Conclusions. Slow infusion of diazoxide causes an 
effective and gradual decrease of BP in patients with 
hypertensive crisis, as well as in those with severe 
hypertension. The exaggerated initial fall, which has 
almost invariably been observed after bolus injec­
tion, can be avoided, thus decreasing the risk of 
serious complications. Addition of a beta-adreno-
ceptor blocking agent results in a slight extra fall of 
systolic BP, whereas diastolic BP remains virtually 
unchanged, despite marked reduction of HR and 
moderate decrease of PRA. The beneficial conse­
quence of this marked decrease of HR without 
substantial fall of BP is probably a smaller risk of 
myocardial ischemia. Although our results show that 
there is not a great difference whether the beta 
blocker is administered before or after diazoxide 
infusion, we prefer to give the beta blocker first. The 
protocol of this study rendered it necessary to wait 
60 minutes after the administration of the beta 
blocker before giving diazoxide. However, in clinical 
practice it seems preferable to curtail the period of 
high BP by proceeding with the infusion of diazox­
ide immediately after the injection of the beta 
blocker. When there is a large fall of BP during 
diazoxide infusion, this treatment can be easily 
interrupted. After diazoxide discontinuation, the 
BP shows no further decline. Although we have not 
observed such an undesirably large fall of BP in any 
of our patients, this complication remains a possibil­
ity. In the rare patient in whom it might occur, the 
regimen that we have advised provides optimal 
safety. 
The authors gratefully acknowledge the assistance of Mieke 
Thissen-Jansen who performed the plasma renin activity 
assays 
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Chapter Vili 
ACUTE TREATMENT OF HYPERTENSION WITH NIFEDIPINE 
F.Th.M. Huysmans, Th. Thien and R.A.P. Koene 
Department of Internal Medicine, Division of Nephrology and 
Out-patient Clinic, Sint Radboudziekenhuis, University of 
Nijmegen, The Netherlands 
SUMMARY 
The calcium antagonist nifedipine, administered sublingually 
in a dose of 10 or 20 mg, lowered blood pressure safely in 
hypertensive patients by 13.5 + 1.2% (n=35) and 19.7 + 2.8% 
(n=16) respectively. It was also effective in hypertensive 
crisis, present in 10 out of these 51 patients. The blood 
pressure reduction was maximal within one hour and sustained 
for at least three hours (n=14). The response was less than 10 
per cent in one third of the patients. The most frequently 
occurring side-effect, flushing, and the observed rises in 
heart rate and PRA, fit with the concept that nifedipine exerts 
its antihypertensive effect by direct vasodilation. The observed 
rises of haematocrit, haemoglobin concentration, total serum 
protein and serum albumin levels indicate an acute decrease of 
plasma volume after the administration of nifedipine. 
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INTRODUCTION 
All factors influencing vascular smooth muscle tone finally 
exert their vasoconstricting or vasodilating effect by inter-
ference with the regulation of the intracellular free calcium 
concentration, and thereby of the excitation-contraction coup-
ling (1). Inhibition of the influx of calcium into the vascular 
smooth muscle cell is one possibility to reduce this concentra-
tion. By this mechanism, the so-called calcium channel blockers, 
or calcium antagonists for short, can induce dilatation of both 
peripheral resistance arterioles and coronary arteries. More-
over, the calcium antagonists have a direct negative inotropic 
and chronotropic effect on the heart (2). Because of these 
properties the calcium antagonists have been used on a large 
scale in patients with angina pectoris or with cardiac arryth-
mias, and in either condition these drugs have been shown to 
be very effective. In comparison with other calcium antagonists 
nifedipine is a drug with potent vascular smooth muscle relaxing 
effects, especially in coronary arteries. Therefore, the use of 
nifedipine has particularly been advocated in Prinzmetal's 
angina (3) . 
Since in most types of hypertension an elevation of the peri-
pheral vascular resistance, which depends on the tone of vascu-
lar smooth muscle, is the main haemodynamic abnormality (4), 
the effects of nifedipine have also been tested in recent years 
in patients with hypertension (5-10). Most of the patients in-
vestigated in these studies had a normal renal function. Based 
on the first positive reports in the literature, we have under-
taken a study of the acute effects of nifedipine in patients 
with hypertension or a hypertensive crisis. A large majority of 
these patients had a decreased renal function. Nifedipine 
reduced blood pressure effectively and safely in most of these 
patients. The accompanying increases in heart rate and plasma 
renin activity (PRA) suggest that nifedipine exerts its effect 
by direct vasodilation. 
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PATIENTS AND METHODS 
We treated 51 adult hypertensive patients with nifedipine cap­
sules sublingually. Thirty five received 10 mg (group A) and 
the remaining 16 patients 20 mg of nifedipine (group B). Their 
clinical data are summarized in Table 1. Only three patients of 
group A and one of group В had an endogenous creatinine clear­
ance of over 100 ml/min. Hypertensive crisis was defined as a 
diastolic blood pressure of over 130 mmHg and a retinopathy 
grade III or IV, or as a diastolic blood pressure above 100 mmHg 
with clear signs of hypertensive encephalopathy. The patients 
without this condition all had a diastolic blood pressure of 
over 100 mmHg measured on at least three occasions in the out­
patient clinic. Fifteen patients of group A and four of group 
В had not received any antihypertensive drug in the last two 
weeks before the study. Out of 20 patients in group A, who were 
treated for their hypertension at the start of the study, 19 
were on a beta-adrenergic blocking agent and 17 on a diuretic 
agent. In the 12 treated patients of group В these numbers were 
10 and 11 respectively. 
During the study the patients were in the supine position and 
their blood pressures were recorded every two minutes with an 
automatic device (Arteriosonde 1217) from 30 min before until 
60 min after the administration. In 14 patients blood pressure 
was recorded for another two hours. Heart rates were recorded 
immediately before and at 10 min intervals during one hour 
after the administration of nifedipine. In 25 patients heart 
rates were calculated from ECG-strips taken at these points. 
Blood samples were drawn before and at 60 min after the admini­
stration of the drug for determinations of haematocrit and 
haemoglobin concentration (n=21), creatinine (n=24), urea (n=23), 
urate (n=23), sodium (n=17), potassium (n=17), chloride (n=17), 
bicarbonate (n=17), glucose (n=24), total protein (n=19), 
albumin (n=9), aldosterone (13) (n=10), and PRA (14) (group A: 
n=19, group B: n=ll).In the first blood samples plasma calcium 
(n=31) and phosphate (n=33) were also determined. 
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Table 1. Clinical data of 51 hypertensive patients treated with 
nifedipine sublingually 
Dose of nifedipine (mg) 
Number of patients 
Male/female 
Age (years)* 
Systolic blood pressure 
Diastolic blood pressure 
Cause of hypertension 
essential 
renal 
renovascular 
other 
Hypertensive crisis 
(mmHg)* 
(mmHg)* 
Endogenous creatinine clearance (ml/min)* 
Left ventricular hypertrophy** 
Hypertensive retinopathy' 
grade 0 
grade I-II 
grade III-IV 
в-»* 
( 
39 
181 
115 
51 
Sroujç 
10 
35 
> Ά 
15/20 
.8 + 
.4 + 
.7 + 
12 
19 
2 
2 
8 
.3 + 
10 
11 
17 
7 
14. 
26, 
15. 
35. 
.6 
.9 
.8 
.5 
( 
36 
189 
ИЗ 
37 
Згоир В 
20 
16 
6/10 
.2 + 11, 
.1 + 18, 
.8 + 13. 
2 
13 
1 
0 
2 
.2 + 37. 
3 
9 
6 
1 
.0 
.3 
.4 
.5 
* Mean values + S.D. 
•» According to the ECG criteria of Romhilt and Estes (11) 
**# According to the criteria of Keith et al. (12) 
Blood pressure values given below are always the means of five 
consecutive readings before and of three at the indicated time 
after the intake of the drug. Mean arterial pressure (MAP) was 
calculated as the sum of the diastolic blood pressure and one 
third of the pulse pressure. A response to nifedipine was de­
fined as a decrease of MAP of more than 10%. If the time is not 
indicated, the data given are the changes at 6 0 min after the 
administration of nifedipine. Mean values + S.E.M. are given 
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below. Statistical comparisons between groups were made with 
Student's t-test for unpaired observations. Changes within a 
group were tested with Student's t-test for paired observations, 
except the changes in PRA and aldosterone which were tested 
with Wilcoxon's rank sum test. Correlations were calculated 
according to Pearson. A P-value of 0.05 was considered as the 
level of statistical significance. 
RESULTS 
Sixty minutes after the sublingual administration of 10 mg 
nifedipine (group A) blood pressure had decreased from 181 + 5/ 
116 + 3 to 156 + 4 / 100 + 2 mmHg. After a dose of 20 mg (group 
B) blood pressure decreased from 189 + 5 / 114 + 3 to 155 + 5/ 
9 0 + 3 mmHg. The fall in blood pressure was never exaggerated. 
The decrease of MAP in group В was significantly greater and 
this difference was already apparent at 10 min after the admi­
nistration of the drug (Fig. 1). In the 14 patients of group A 
in whom the blood pressure was recorded during a longer period 
the decrease of MAP was -13.9 + 2.0, -12.9 + 2.2, -10.7 + 2.1 
and -9.5+2.7% at 60, 90, 120 and 180 min respectively. The 
final blood pressure at 3 hours was still significantly below 
its pretreatment level. In the eight patients with a hyperten­
sive crisis in group A blood pressure decreased from 210 + 9/ 
131 + 5 to 175 + 9 / 112 + 6 mmHg. In the two patients in group 
В with this condition the decrease was from 201 + 12 / 124 + 1 
to 149 + 1 / 8 8 + 3 . The mean decreases of MAP in the different 
groups are compared in Table 2. Twelve out of 35 patients in 
group A and four out of 16 in group В were considered to be 
non-responders, because their decrease in MAP after 60 min was 
less than 10%. Pretreatment blood pressure may have played some 
role in the degree of blood pressure change, since a weak but 
significant negative correlation between these two parameters 
existed in group A (r= -0.35, p<0.05). However, this correla­
tion was not significant in group В (r= -0.39). We found no 
correlations between the percentual reduction of MAP and age, 
body weight, endogenous creatinine clearance, plasma calcium 
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Figure 1. Changes of mean arterial pressure (MAP) and heart rate after 
sublingual administration of nifedipine. The asterisks indicate 
significant differences between observations. 
Mean values ± S.E.M. are shown. 
Table 2. Acute antihypertensive effect of nifedipine 
No. of 
patients 
Decrease of MAP* 
at 60 m m (%)** 
Nifedipine 10 mg 
All patients 
Hypertensive crisis 
35 
8 
-13.5 + 1.2 
-15.1 + 2.6 
Nifedipine 20 mg 
All patients 
Hypertensive crisis 
16 
2 
-19.7 + 2.8 
-27.1 + 2.3 
»MAP = mean arterial pressure , «* Mean values ± S.E.M. 
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content or the plasma calcium values, adjusted for serum protein 
and albumin levels (15). No differences m blood pressure re­
duction were found between males and females, or between pre­
viously treated and untreated patients. Only a weak, negative 
correlation between plasma phosphate levels and the percentual 
changes of MAP was found in group A (r= -0.57, n=22, p<0.01); 
the correlation between these parameters was not significant in 
group В (r= -0.55, n=ll). 
In group A heart rate rose by 11.3 + 2.0% from 77 + 3 to 85 +3 
beats/min and in group В by 21.0 + 3.0% from 78 + 5 to 94 + 6 
beats/min. The rise in heart rate in group В was significantly 
larger than that in group A starting from 30 min after the 
administration of the drug (Fig. 1). No changes in PR-interval 
were observed on the ECG-stnps. 
р р д nifedipine 
(ng/ml h ) 5 0 лп 
3 0 -
2 0 -
10-
5 -
3 -
2 -
1-
b a b a 
Figure 2. Plasma renin activity (PRA) before (b) and 60 m m after (a) 
sublingual administration of 10 mg (left panel) and 20 mg (right 
panel) of nifedipine. 
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Fig. 2 shows the individual changes in PRA after nifedipine. 
The mean rise of PRA was 20.9 + 7.3% after 10 mg and 34.6+ 8.43 
after 20 mg. These changes were not significantly different 
between the two groups. We found no significant correlations 
between the changes in blood pressure, heart rate and PRA. 
Plasma aldosterone levels did not change. 
Plasma sodium levels showed a small but significant increase 
from 140.5 + 0.6 to 140.9 + 0.6 mmol/l (p<0.01), whereas the 
rise of plasma chloride was not significant. We observed no 
changes in plasma potassium, bicarbonate, creatinine, urea, 
urate, or glucose levels. We found slight, but significant in-
creases of haematocrit and haemoglobin concentrations, and of 
the serum levels of total protein and albumin after nifedipine 
(Table 3). 
Table 3. Haematocrit, plasma haemoglobin concentration, and serum levels 
of total protein and albumin before and after administration of 
nifedipine 
Haematocrit (l/D 
Haemoglobin (mmol/l) 
Total protein (g/1) 
Albumin (g/1) 
No. 
21 
21 
19 
9 
Before 
0.361 + 0.079 
7.67 + 1.73 
65.6 + 7.0 
35.4 +5.2 
After 
0.375 
7.91 
69.0 
37.4 
+ 
+ 
+ 
+ 
0, 
1. 
7, 
7, 
.083 
,73 
.1 
.1 
P-
< 
< 
< 
< 
-value 
0.0005 
0.0002 
0.0001 
0.05 
* Mean values +_ S.E.M. 
The side-effects of nifedipine are listed in Table 4. Serious 
complications were not observed. Flushing was the most commonly 
occurring symptom in both groups. It did not only appear as a 
subjective complaint but was always easily discernible as a 
clear reddening in the face. In the patients who received 20 mg 
of nifedipine the decrease of MAP was significantly larger in 
those who showed flushing, being -28.1 + 1.6% (n=7) versus 
-13.0 + 3.4% (n=9) in the patients, who did not show flushing. 
This was not the case in the lower dosage group. 
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Table 4- Number of patients with side-effects after 10 mg (group A) 
and 20 mg (group B) of nifedipine sublingually* 
Group A (n=35) Group В (n=16) 
Flushing 7 (20) 7 (44) 
Headache 4 (11) 5 (31) 
Dizziness 1 (3) 1 (6) 
Palpitations 2 (6) 1 (6) 
Nausea, vomiting 0 (0) 1 (6) 
« Percentages in parentheses 
DISCUSSION 
In this study nifedipine, administered sublingually, lowered 
blood pressure quickly and effectively in the majority of hyper­
tensive patients. This decrease in blood pressure was sustained 
during several hours. A dose of 20 mg was clearly more effective 
than 10 mg, although even after the higher dose one fourth of 
the patients showed a response of less than 10%. Lederballe-
Pedersen et al. (9) also found a weak correlation between the 
pretreatment blood pressure and the response to nifedipine, 
whereas there was no blood pressure reduction at all in normo-
tensive subjects. This could partly be related to a greater 
sensitivity of the vessel wall to calcium antagonists in hyper­
tension, as has been demonstrated in vitro for aorta strips of 
hypertensive and normotensive rats (16). In older patients who 
have a less efficiently functioning baroreceptor reflex arch 
(17), a larger blood pressure response to nifedipine could have 
been expected. However, we did not find a significant correla­
tion between age and the blood pressure lowering effect of 
nifedipine. Theoretically, a synergism between nifedipine and 
other antihypertensive agents is possible, but in this acute 
study the blood pressure decrease after nifedipine was not 
larger in previously treated patients. Because calcium antago­
nists specifically inhibit the influx of calcium into the cells, 
102 
pre-existent disturbances of calcium metabolism might influence 
the response to nifedipine. In group A blood pressure decreased 
more in patients with higher plasma phosphate levels, whereas 
pretreatment blood pressure was not higher in these patients. 
One could speculate that this is due to lower plasma calcium 
levels, which generally decrease in proportion to the rise of 
plasma phosphate levels (18). However, we found no correlation 
between blood pressure decrease and plasma calcium levels. Also 
renal function did not influence the response to nifedipine. 
The variation of the blood pressure lowering effect of nifedi-
pine could be related to differences in plasma levels of the 
drug, but Lederballe-Pedersen and Mikkelsen (19) only found a 
correlation between these levels and the decrease of forearm 
vascular resistance and not with the decrease in blood pressure. 
Despite the negative chronotropic effect of nifedipine in vitro 
(2), heart rate increased after its administration whereas 
electrocardiographically no increase of the PR-interval was 
observed. The direct negative chronotropic effect of nifedipine 
is probably outweighed by a reflex adrenergic stimulation (2) 
and perhaps also by withdrawal of parasympathetic tone (20), 
which occurs as a consequence of vasodilation. This finding of 
increased heart rates differs from those in studies that used 
other calcium antagonists, with stronger direct negative chro-
notropic effects and smaller vascular smooth muscle relaxing 
effects (2). These negative chronotropic and negative inotropic 
effects of calcium antagonists might make it hazardous to com-
bine them with beta-blocking agents (21,22). It is possible 
that this restriction does not apply to nifedipine, because of 
its relatively strong vasodilatory as compared to its negative 
inotropic and chronotropic action. 
Not only the rise in heart rate, but also the observed increase 
of PRA fits with the concept, that nifedipine exerts its anti-
hypertensive effect by direct vasodilation (23) and this also 
holds for the flushing which occurred as the most frequent side-
effect. Others (7,8,9) have confirmed this by measurement of 
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the systemic or forearm vascular resistance. The absence of a 
rise of aldosterone secretion could be due to a direct inhibi-
tion of the stimulatory effect of angiotensin-II on aldosterone 
secretion (24). 
Although blood pressure reduction due to vasodilation may in-
duce a decrease of glomerular filtration rate (25), we observed 
no rise of plasma creatinine, urea or urate levels. This is 
probably due to the short observation period of only 60 min. 
Surprisingly, haematocrit, plasma haemoglobin, total serum 
protein, and albumin levels rose slightly but significantly 
after nifedipine administration. We ascribe these increases to 
a decrease of plasma volume. This could be the consequence of 
an adrenergically mediated constriction of the capacitance 
vessels, of a direct diuretic effect of nifedipine (26) or of a 
modest blunting of the response of the kidney to vasopressin 
(27). This latter effect might also explain the small rise in 
plasma sodium concentrations that we observed. Further studies 
will be needed to elucidate this phenomenon. 
Some investigators incidentally observed a rise of plasma glu-
cose levels after blood pressure reduction with several direct-
ly acting vasodilating agents, which they ascribed to a reflex 
adrenergic stimulation (28) . We observed no change of plasma 
glucose levels and this is in accordance with the data of Ueda 
et al. (8), who only found a transient increase of free fatty 
acid levels in the plasma. 
In conclusion, nifedipine is a useful and safe drug in situations 
where a rapid reduction of high blood pressure is required. 
Since it is so easy to administer and does not induce sudden 
hypotension, it seems even suited to be used as a first drug 
for the acute treatment of hypertension. Its rapid onset of 
action allows early detection of an unsatisfactory blood pressure 
response. Thus, a potentially hazardous delay in the switch to 
another antihypertensive regimen can be avoided. 
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GENERAL DISCUSSION 

GENERAL DISCUSSION 
In the preceding chapters we have reported on our experience in 
hypertensive patients with the administration of agents, that 
all have vasodilating properties, but which differ in their 
mechanism of action. In chapter II we have described the use of 
one of these agents, saralasin, a competitive inhibitor of angio-
tensin-!!, to assess the role of the renin-angiotensin system in 
sustaining hypertension. In the subsequent chapters the results 
of acute and chronic treatment of hypertension with other vaso-
dilating agents are described. In the following we will comment 
briefly on these results. We will pay attention to the role 
of the vasodilator induced compensatory reactions which antago-
nize the antihypertensive effect of these agents and the conse-
quent possibility of synergistic antihypertensive activity if 
these agents are combined with other drugs. Also the influence 
of these compensatory reactions and of the different mechanisms 
of action on the occurrence of side-effects will be discussed 
briefly. Finally, some remarks on new developments in vasodila-
tor therapy will be made. 
The renin-angiotensin system 
In chapter II it has been shown that the renin-angiotensin 
system and blood volume are two important factors in sustaining 
haemodialysis-resistant hypertension. However, the role of 
other factors cannot be excluded. Two out of the 12 hypertensive 
patients showed no fall of blood pressure during saralasin 
administration, although their blood volumes were not abnormally 
high. This suggests, that in these patients other unknown 
pressor mechanisms were operative. Although the renin-angio-
tensin system in haemodialysis patients is reported to be com-
parable to that in other patients, simple extrapolation of the 
results of this study to patients with hypertension who are not 
on dialysis is probably not justified, since haemodialysis per 
se induces many complex changes. Other studies, however, under-
line the important role of the renin-angiotensin system and 
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volume status in the development of high blood pressure in 
patients with renal disease not on chronic haemodialysis (1), 
but also in patients with essential hypertension (2). Once 
renin-dependency of hypertension in dialysis patients has been 
demonstrated with the aid of saralasin, an attempt to treat 
these patients with agents interfering with this system, such 
as a beta-adrenoceptor blocking drug or a converting enzyme 
inhibitor (3) is a logical following step; bilateral nephrec-
tomy must be considered in drug-resistant cases but also in 
young patients who need many drugs to control blood pressure. 
Antihypertensive effect of vasodilating drugs 
Prazosin appeared to lower blood pressure more in the standing 
than in the supine position. This can be understood from its 
mechanism of vasodilation, which is based on blockade of alpha.-
adrenoceptors, and not, as was previously assumed, on direct 
vasodilation. The antihypertensive effect in the supine 
position was disappointing. This is in contrast with the general 
opinion on the effectiveness of this drug (4). To substantiate 
our findings, we are now carrying out a cross-over study between 
prazosin and hydralazine, which functions more or less as a 
prototype direct vasodilator. 
The other drug whose effectiveness we studied in the chronic 
treatment of hypertension was minoxidil. Although it was very 
effective in lowering blood pressure, the overall success rate 
was not 100 per cent. It must be taken into account, that 
patient compliance could have played a role in the evaluation 
of the therapeutic efficacy of these drugs. This problem did 
not exist in the acute studies. Yet, nine of the 81 patients 
receiving diazoxide by slow intravenous infusion and even a 
larger proportion of patients treated with nifedipine sub-
lingually showed a blood pressure decrease of less than 10 per 
cent and were therefore classified as non-responders. Since two 
patients did show a response to the second, but not to the 
first diazoxide infusion, dosage may have played a role. The 
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larger blood pressure lowering effect of 20 as compared to 10 
mg nifedipine is also an argument for the role of the dose 
level. However, these factors cannot explain the unsatisfactory 
results in each unresponsive patient. 
The question arises to which extent the vasodilator induced 
reactions antagonize its antihypertensive effect. The observed 
sodium retention, rises in heart rate and cardiac output, and 
in plasma renin activity could all have diminished the anti-
hypertensive effect of the vasodilators investigated. Sodium 
retention has been combated in the patients treated with 
minoxidil by changing chlorthalidone to furosemide, a drug 
with much stronger natriuretic properties. Although this reduced 
oedema and body weight, blood pressure was not lowered further. 
We also observed the same phenomenon after addition of a 
diuretic agent during chronic treatment of hypertension with 
diazoxide (5). These observations suggest, that sodium retention 
does not exert a very important antagonistic effect. 
Because of the relationship between blood pressure, cardiac 
output, and peripheral resistance, it is evident that the 
vasodilator induced rise in cardiac output, largely a conse-
quence of a rise in heart rate, opposes its antihypertensive 
effect. On the other hand, an important antagonistic effect 
of the rise of plasma renin activity after vasodilation has 
been demonstrated (6). Yet, intravenous administration of a 
beta-blocker after diazoxide infusion resulted in hardly any 
further decrease of blood pressure, despite immediate reductions 
of heart rate and plasma renin activity. The observation 
period could have been too short to discover a large effect of 
the beta-blocker on blood pressure, but this is unlikely since 
Man in 't Veld et al. (7) did not find a larger hypotensive 
effect of diazoxide bolus injections during chronic treatment 
with propranolol than without preceding beta-blockade. However, 
also after previous beta-blockade diazoxide induced a rise of 
heart rate, largely due to parasympathetic withdrawal (7), and 
of plasma renin activity. Therefore, the counteracting role of 
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these mechanisms cannot be excluded. The effects of beta-
blockade after chronic treatment with diazoxide are very inte­
resting in relation to this problem. Fig. 1 (8) shows that 
diazoxide administered orally as a single agent during five 
days, reduced blood pressure by 13 per cent. Addition of a 
beta-blocker further reduced blood pressure, already on the 
first day of its administration by another 24 per cent. This 
effect of beta-blockade on blood pressure is much larger than 
generally observed when the drug is used alone. For comparison, 
the data of the acute study of the effects of beta-blockade 
after diazoxide infusion are also represented in the figure. 
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Figure 1. The percentual changes of mean arterial pressure (ΔΜΑΡ), heart 
rate (ΔΗΗ) and plasma renin activity (APRA) from control values 
(C) after acute, intravenous (left panel, n=13) and chronic, 
oral (right panel, n=8) treatment with diazoxide (D) and after 
additional beta-blockade (+0). 
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This figure shows clearly, that the effects of beta-blockade 
on heart rate and plasma renin activity were comparable after 
acute and chronic diazoxide administration, but that its effect 
on blood pressure under either circumstance was completely 
different. These data suggest that after chronic treatment with 
diazoxide alone a compensatory mechanism becomes operative, 
which can be inhibited by a beta-blocker but is not related to 
heart rate or plasma renin activity. A second possibility is 
that a mechanism, that normally antagonizes the effect of beta-
blockade on blood pressure, is switched off by preceding chronic 
diazoxide administration. Further investigations to resolve this 
interesting problem are required. Whatever the explanation may 
be, the above-mentioned results (8) and several other studies 
(5,9) point to a synergism in lowering blood pressure between 
a beta-blocker and a vasodilator when they are used for chronic 
treatment. This is of importance in clinical practice. 
Another compensatory mechanism, dependent on the alpha-sympa-
thetic tone, might also be active in antagonizing the effects 
of antihypertensive drugs. Koch-Weser stated, that directly 
peripherally acting vasodilators can overcome the sympatheti-
cally induced arteriolar constriction. Nifedipine also induces 
sympathetic stimulation and a rise of plasma noradrenaline 
levels (10). However, Van Meel et al. (11) suggested that this 
calcium-antagonist exerts its vasodilating effect by selective 
inhibition of alphaj-adrenoceptor mediated vasoconstriction. 
On theoretical grounds it would, therefore, be interesting to 
examine whether nifedipine and the alpha^-adrenoceptor blocking 
agent prazosin are synergistic in lowering blood pressure. 
Whether such a combination will be of practical use, is question-
able since it would exert the same vascular effects as a classi-
cal alpha-adrenoceptor (alpha 1+2) blocking agent, such as 
phenoxybenzamine. The only advantage of this combination could 
be a smaller rise in heart rate, provided that nifedipine does 
not interfere with the alpha2-adrenoceptor mediated negative 
feed-back of noradrenaline on its own secretion. The new findings 
on the mechanism of action of nifedipine may have consequences 
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for the Classification of vasodilators. The possible interaction 
of calcium antagonists with alpha.-adrenoceptor stimulating 
agents may make it necessary to place them in a group separate 
from the so-called direct vasodilators. 
Side-effects of vasodilating drugs 
In addition to the efficacy in lowering blood pressure, the 
incidence and severity of side-effects are important determinants 
of the therapeutic usefulness of a vasodilating agent. The 
side-effects observed during prazosin treatment, are clearly 
inherent to its mechanism of action, i.e. blockade of the 
alpha.-adrenoceptors. In our opinion, the available alpha-
adrenoceptor blocking drugs can therefore not be drugs of first 
choice, if vasodilation is required in the antihypertensive 
regimen. Moreover, prazosin was in our experience hardly effective 
in lowering supine blood pressure. 
The side-effects observed during treatment of hypertension 
with directly acting vasodilators, are related to some of the 
compensatory reactions. During chronic treatment with a vasodi-
lator the rise in heart rate is accompanied by palpitations, 
necessitating addition of a beta-blocker, as we saw in the 
treatment of patients with minoxidil. Acute blood pressure 
reduction with intravenous diazoxide also causes a rise in 
heart rate and cardiac output, which increases the risk of 
myocardial ischaemia due to hypoperfusion after a large fall 
in blood pressure. Here, beta-blockade as well as controlled 
reduction of blood pressure by replacing administration of 
diazoxide as a bolus injection by slow infusion, will diminish 
this risk. The headache after vasodilation also has generally 
been attributed to the rise in heart rate and consequently in 
cardiac output, and can predictably be prevented by beta-
blockade as well. 
Chronic treatment with minoxidil caused sodium retention and 
oedema formation. The mechanism of vasodilator induced sodium 
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retention and oedema formation has been extensively discussed 
by Thien (12). In short, sodium retention could be the conse-
quence of a lower perfusion pressure in the kidney and of an 
increase of aldosterone secretion, induced by the rise in 
plasma renin activity. This can however not explain why 
oedema occurs, because the volume expansion would lead to an 
escape mechanism with consequent natriuresis such as occurs in 
primary aldosteronism, unilateral renal artery stenosis, and 
inappropriate secretion of antidiuretic hormone. It seems more 
likely that oedema formation is the primary event and that it 
results from a disturbance of the Starling mechanism caused 
by an increase of the intracapillary hydrostatic pressure after 
dilatation of the resistance arterioles. This may explain the 
larger increase of body weight in older patients during treat-
ment with diazoxide, because they probably have a greater tissue 
compliance (8). 
We have observed decreases in renal function after acute treat-
ment with diazoxide and at the start of chronic treatment with 
minoxidil and diazoxide (5,13). We ascribe this to a reduction 
in renal perfusion pressure, and not to a direct toxic effect 
of these drugs on the kidney, since a correlation between 
blood pressure reduction and changes in renal function during 
chronic vasodilating therapy has been found (12). On the other 
hand, the decrease of renal function in patients with renal 
disease can be delayed by adequate treatment of an existing 
hypertension (14). Our experience with the acute effects of 
nifedipine seemed to be an exception to the rules that apply 
for most vasodilators. No signs of a decrease of renal function 
were observed, while there were even indications for an acute 
decrease of plasma volume. More investigations are needed to 
elucidate these apparently controversial findings. 
The hypertrichosis, that we observed during chronic treatment 
with minoxidil, is probably related to the vasodilation per 
se, since this side-effect has also been observed with the un-
related vasodilator diazoxide (13). It is evident, that the 
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flushing after administration of nifedipine, which was related 
to the antihypertensive effect of this drug, is due to dilatation 
of the skin vessels. This strongly suggests, that the periphe-
rally acting vasodilators not only differ in their mechanism 
of action, but also in selectivity with regard to various vas-
cular beds. In man only a few studies have been done in this 
field. 
New developments in vasodilation 
Since the vasodilating agents described here have so many side-
effects and do not always lower blood pressure sufficiently, 
the need for other, better vasodilating agents still exists. 
Captopril is a newly developed vasodilating agent, that in-
hibits the enzyme converting angiotensin-I into angiotensin-II. 
Since the renin-angiotensin system appears to play an important 
role in sustaining dialysis-resistant but also many other types 
of hypertension, it may be of value in antihypertensive therapy 
(3). It has been demonstrated, that it is especially effective 
in combination with diuretic agents, presumably because these 
drugs stimulate the renin-angiotensin system (3). Because 
directly acting vasodilators also stimulate this system, a 
synergism in blood pressure reduction between those drugs and 
Captopril may be expected. As far as side-effects are concerned, 
Captopril has some important advantages over the directly 
acting peripheral vasodilators: for unknown reasons it causes 
no increase of heart rate, nor does it induce hypertrichosis 
or oedema. The absence of oedema formation could be related to 
the suppression of angiotensin-II generation, and thereby of 
aldosterone secretion. Summarizing, the results in treating 
hypertension with Captopril are promising, but its definitive 
place still has to be established. 
Several other new vasodilating drugs are under investigation 
now: hydralazine dérivâtes up to now not causing a lupus-
like syndrome, an agent antagonizing the effects of serotonin 
(ketanserin), and PNMT-inhibitors which inhibit the generation 
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of adrenaline from noradrenaline in the adrenal medulla, thus 
reducing the stimulation of the presynaptic beta-receptors and 
thereby of the release of noradrenaline in the synaptic cleft. 
In conclusion, the renin-angiotensin system plays an important 
role in sustaining hypertension under many circumstances, by 
a direct effect of angiotensin-II on the resistance arterioles. 
This is one of the causes of the elevation of the peripheral 
resistance, observed in most types of hypertension. Irrespective 
of the cause of this elevation, the available directly acting 
peripheral vasodilators are generally effective in acute and 
chronic treatment of hypertension. The side-effects of these 
vasodilators can be substantially reduced by combining them 
with a diuretic and a beta-adrenoceptor blocking agent. More-
over, in chronic treatment of hypertension vasodilators and 
beta-blockers are synergistic. More investigations of this 
interaction and that of vasodilators with other drugs are needed, 
to clarify the role of vasodilator compensatory mechanisms as 
well as to achieve a higher therapeutic efficacy. 
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SAMENVATTING 

SAMENVATTING 
Bij de meeste patiënten met een langer bestaande hypertensie 
is, onafhankelijk van de oorzaak van de bloeddrukverhoging, een 
toegenomen perifere vaatweerstand de belangrijkste hemodynami-
sche afwijking, terwijl het hartminuutvolume meestal normaal 
is. Het mechanisme, waarop het toenemen van de perifere weer-
stand bij de verschillende vormen van hypertensie berust, staat 
ter discussie. De krachtige endogene vaatvernauwende stof 
angiotensine-II kan de perifere weerstand, en daarmee de bloed-
druk, sterk doen toenemen, en zou daarom een belangrijke factor 
in genoemd mechanisme kunnen zijn. Hiernaar werd onderzoek ver-
richt bij patiënten met een terminale nierinsufficiëntie, bij 
wie hypertensie bleef bestaan ondanks krachtige pogingen tot 
het onttrekken van water en zout middels ultrafiltratie tijdens 
hemodialyse. Bij het merendeel van deze patiënten kon met behulp 
van saralasine, een competitieve antagonist van angiotensine-II, 
worden aangetoond dat het renine-angiotensinesysteem een belang-
rijke rol speelt bij het handhaven van deze dialyse-resistente 
hypertensie. 
Naast een dergelijk diagnostisch gebruik van een middel, dat 
de weerstandsarteriolen kan verwijden, vinden vaatverwijders 
in de klinische praktijk vooral therapeutische toepassing. Dit 
ligt ook voor de hand gezien de bovengenoemde verhoging van de 
perifere weerstand bij hypertensie. De effecten op lange termijn 
van de direct perifeer aangrijpende vaatverwijder minoxidil en 
van het aanvankelijk ook als zodanig geïntroduceerde prazosine 
werden onderzocht bij patiënten met hypertensie. Het laatste 
van deze twee middelen bleek de bloeddruk bij de patient in 
liggende houding slechts weinig te verlagen. De bijwerkingen, 
waarvan orthostatische hypotensie en duizeligheid het meest 
frequent optraden, zijn grotendeels toe te schrijven aan het 
werkingsmechanisme van prazosine, dat op blokkering van de 
perifere alpha^-receptoren berust. Minoxidil bleek de bloeddruk 
zowel bij de patient in liggende als in staande houding veel 
effectiever, maar nog niet in alle gevallen voldoende te ver-
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lagen. Ook het gebruik van minoxidil ging gepaard met vele 
hinderlijke bijwerkingen, waarvan het optreden van tachycardie 
en oedeem de toevoeging van respectievelijk een beta-blokkeer-
der en het krachtige diureticum furosemide noodzakelijk maakte. 
De effectiviteit van een bloeddrukverlagend middel is vooral 
van vitaal belang bij de behandeling van de hypertensieve 
crisis, waar de bloeddruk in tamelijk korte tijd verlaagd moet 
worden. Diazoxide, een andere krachtige vaatverwijder, wordt 
bij deze direct levensbedreigende ziekte de laatste jaren steeds 
vaker toegepast vanwege zijn effectiviteit en snel intredende, 
lang aanhoudende werking. Volgens de literatuur zou dit middel, 
om effectief de bloeddruk te kunnen verlagen, juist bij een 
hypertensieve crisis via een zeer snelle intraveneuze injectie 
toegediend moeten worden. Deze snelle intraveneuze toediening 
van diazoxide veroorzaakt een abrupte, onvoorspelbare en soms 
ongewenst sterke daling van de bloeddruk en heeft daardoor in 
het verleden herhaaldelijk tot ernstige neurologische compli-
caties en tot ischemie of zelfs infarcering van het myocard 
geleid. Daarom werd de noodzaak tot snelle toediening van dia-
zoxide onder deze omstandigheden opnieuw onderzocht. Bij een 
klein aantal patiënten met een hypertensieve crisis bleek lang-
zame infusie van diazoxide de bloeddruk even effectief te 
verlagen als een snelle injectie. Langzame infusie van diazoxide 
bleek bij een grote groep van patiënten met een hypertensieve 
crisis even effectief als bij patiënten met een ernstige hyper-
tensie zonder deze levensbedreigende complicatie. Omdat de 
daling van de bloeddruk tijdens langzame infusie van diazoxide 
veel geleidelijker en beter stuurbaar is dan na een snelle 
injectie, verdient de eerste toedieningsvorm verre de voorkeur. 
Echter ook bij langzame toediening van diazoxide gaat de daling 
van de bloeddruk gepaard met een stijging van de hartfrequentie, 
zodat het risico van myocardischemie blijft bestaan. Daarom 
werd diazoxide-infusie gecombineerd met toediening van een 
beta-blokkeerder. Aldus bleek een stajging van de hartfrequentie 
voorkomen te kunnen worden zonder dat er een noemenswaardige 
versterking van het bloeddrukverlagende effect van diazoxide 
126 
ontstond, zodat het risico van cardiale complicaties verkleind 
werd. 
Ook onderzochten wij het antihypertensieve effect van nifedipine. 
Dit middel behoort tot de Calciumantagonisten, een nieuwe groep 
van farmaca met vaatverwijdende eigenschappen. Men kan het een-
voudigweg sublinguaal toedienen. Nifedipine bleek bij eengroot 
gedeelte van de onderzochte patiënten de bloeddruk snel en 
effectief te kunnen verlagen zonder ernstige bijwerkingen te 
veroorzaken. Evenals bij toepassing van andere vaatverwijders 
werd ook na toediening van nifedipine een stijging van de hart-
frequentie en van de plasma renine-activiteit waargenomen. 
In hoeverre deze stijgingen van hartfrequentie en plasma renine-
activiteit, en de door vaatverwijders geïnduceerde natriumre-
tentie het antihypertensieve effect van deze middelen tegengaan 
is overigens nog niet duidelijk. Zeker is dat deze compensatoire 
reacties een rol spelen bij het optreden van bijwerkingen als 
hartkloppingen, hoofdpijn en oedeem. Dit maakt combinatie van 
een vaatverwijder met een beta-blokkeerder en een krachtig 
diureticum vaak noodzakelijk, zoals geconstateerd werd tijdens 
de behandeling met minoxidil. De in gebruik zijnde vaatverwij-
ders hebben naast de hier genoemde nog andere, al dan niet aan 
hun werkingsmechanisme inherente bijwerkingen. Bovendien ver-
lagen zij niet bij alle patiënten de bloeddruk in voldoende 
mate. Daarom bestaat er nog steeds behoefte aan andere krach-
tige vaatverwijders met minder bijwerkingen. 
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WOORDEN VAN DANK 
Allen, die hebben bijgedragen aan het tot stand komen van dit 
proefschrift, wil ik hier van harte bedanken. In de allereerste 
plaats ben ik veel dank verschuldigd aan de patiënten, zonder 
wier bereidwillige medewerking dit onderzoek onmogelijk zou 
zijn geweest. 
Vaak heb ik bij de uitvoering van het onderzoek een succesvol 
beroep kunnen doen op Do van Schayk, Eugenie Burm en de andere 
verpleegkundigen van de kunstnierafdeling, de verpleegafdeling 
nierziekten en de polikliniek voor inwendige ziekten. 
Mevrouw A. Felten-Chardon en Magda van de Manacker van de iso-
topenafdeling van de kliniek voor inwendige ziekten hebben met 
zeer veel zorg de plasma- en bloedvolumina van de haemodialyse-
patienten bepaald. 
Het grote aantal bepalingen van de plasma renine-activiteit en 
van de aldosteronspiegels werd uitgevoerd in het laboratorium 
van de afdeling experimentele en chemische endocrinologie door 
Mieke Thissen-Jansen en Angeline van Geel. Het overige bloed-
onderzoek werd verricht in het klinisch chemisch laboratorium 
van de kliniek voor inwendige ziekten. 
De tekeningen in dit proefschrift werden merendeels vervaardigd 
door Cees Nicolasen van de afdeling medische illustratie en 
gefotografeerd door medewerkers van de afdeling medische foto-
grafie. 
De heer E. de Graaff van de medische bibliotheek is mij steeds 
behulpzaam geweest met het opzoeken van soms moeilijk te vinden 
literatuur. 
Tenslotte wil ik Angele Wentholt en Ilse Hilgers-Biermans be-
danken voor het met veel geduld en zorgvuldig typen van de ver-
schillende versies van de hier opgenomen artikelen, en ook Erna 
Kokke, die bovendien met grote nauwgezetheid het uiteindelijke 
manuscript persklaar heeft gemaakt. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 5 augustus 
1945 te 's-Hertogenbosch. Vanaf 1956 bezocht hij in die stad 
het Sint-Janslyceum, alwaar hij in 1962 het getuigschrift 
gymnasium-g behaalde. Daarna studeerde hij wiskunde aan de 
Katholieke Universiteit te Nijmegen tot november 1963. Aanslui-
tend studeerde hij geneeskunde aan dezelfde universiteit en 
behaalde het doctoraalsexamen in 1968 en het artsexamen in 
maart 1971. Na in verschillende praktijken werkzaam te zijn 
geweest als waarnemend huisarts ving hij zijn opleiding tot 
internist aan op de afdeling Interne Geneeskunde van het Sint 
Canisiusziekenhuis te Nijmegen (Hoofd van de opleiding: Dr. 
J.H.J. Enneking), alwaar hij werkzaam was tot april 1977. Op 1 
november 1977 werd hij door de Specialisten Registratie Commissie 
ingeschreven als internist. Vanaf 1 april 1977 is hij als 
internist verbonden aan de afdeling nierziekten van de 
Universiteitskliniek voor Inwendige Ziekten van het Sint 
Radboudziekenhuis te Nijmegen. 
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STELLINGEN 
I 
Bij de acute behandeling van ernstige hypertensie kan men de 
veiligheid van een langzame diazoxide-infusie nog vergroten door 
voorafgaande intraveneuze toediening van een beta-receptor-
blokkeerder. 
II 
Tijdens chronische, echter niet bij acute behandeling met 
diazoxide heeft toevoeging van een beta-receptorblokkeerder een 
sterk en snel optredend bloeddrukverlagend effect. Dit fenomeen 
kan niet verklaard worden uit remming van bekende compensatoire 
reacties na vaatverwijding. 
III 
Dialyse-resistente hypertensie wordt in de meeste gevallen 
onderhouden door een te sterk gestimuleerd renine-angiotensine-
systeem. 
IV 
Door sublinguale toediening van de calcium-antagonist nifedi-
pine kan bij het merendeel van de patiënten met ernstige hyper-
tensie of een hypertensieve crisis de bloeddruk snel, veilig 
en effectief verlaagd worden. 
V 
Vanwege de aan het werkingsmechanisme van alpha-receptor-
blokkeerders inherente bijwerkingen dienen deze stoffen in de 
behandeling van hypertensie met grote terughoudendheid te 
worden toegepast. 
VI 
Met behoud van het antihypertensief effect kan men de hinder-
lijke bijwerkingen van de krachtige vaatverwijder minoxidil 
verminderen door het middel in lage dosis voor te schrijven in 
combinatie met hydralazine. 
P.G.G. Gerlag, persoonlijke mededeling 
VII 
Het verdient aanbeveling te onderzoeken of behandeling met 
vaatverwijders in een vroeg stadium van decompensatio cordis 
de prognose van deze ziekte gunstig beïnvloedt. 
VIII 
Bij de behandeling van urineweginfecties veroorzaakt een dosis 
nitrofurantoine van 4 maal daags 50 mg minder bijwerkingen en 
is even effectief als de in het algemeen geadviseerde dosis van 
4 maal 100 mg. 
R.A.P. Koene (19Θ2) Ned.T.Geneesk. 126, 1290 
IX 
Antithymocytenglobuline zou mogelijk juist dankzij zijn gemeng­
de idiotype-samenstelling minder antilichaamvorming opwekken 
dan een monoclonaal anti-T-lymfосуt antilichaam, en daardoor 
in vivo effectiever kunnen zijn. 
X 
Toediening van prednison kan bij patiënten met een nefrotisch 
syndroom leiden tot een aanzienlijke stijging van de Proteinurie. 
P.G.G. Gerlag, F.H.J.M. van Liebergen en R.A.P. Koene (1982) 
Proc. EDTA, ter perse 
XI 
Chirurgische borstreconstructie na een mamma-amputatie vanwege 
carcinoom belemmert niet wezenlijk de diagnostiek of behandeling 
van een recidief. Vrees voor problemen van dien aard mag dan 
ook geen reden zijn een vrouw een dergelijke kosmetische 
operatie te weigeren. 
L.H. Wilkinson, O.A. Peloso en W.G. Dail (1982) Arch.Surg. 117, 579 
XII 
Uit het feit dat verbod op het uitleven van driftimpulsen kan 
bijdragen tot neurosevorming mag niet de conclusie worden 
getrokken, dat het toelaten of zelfs stimuleren van het uit-
leven van deze impulsen neurose geneest of voorkomt. 
XIII 
De waarde van uitbreiding van het aantal tandwieltjes op de 
pignon van de racefiets wordt door de wielrenner vaak overschat, 
waardoor de stimulans tot trainen en daarmee de prestaties 
minder worden. 
XIV 
Hoewel muziek en wiskunde veel gemeen hebben, is het eindresul-
taat bij af en toe onzuiver redeneren meestal niets waard, 
terwijl dat bij af en toe onzuiver musiceren zeer fraai kan 
zijn. 
XV 
Economen, die juichen over het toenemen van investeringen in 
de industriële sector en groei van de economie en treuren over 
het stijgen van de kosten in de sociale sector en de gezond-
heidszorg, overtuigen meer door hun beroep op zuinigheid dan 
door helderheid van hun betoog. 
XVI 
Efficiency en doelmatigheid in de gezondheidszorg kunnen worden 
verhoogd door niet alleen medische verrichtingen, maar ook het 
op goede gronden achterwege laten daarvan te belonen. 
XVII 
Kritiek op de geneeskunde wordt door gezonde mensen vaak te 
gemakkelijk geleverd, maar gezonde twijfel aan de waarde van 
sommige geneeskundige ontwikkelingen blijft geboden. 
"A l ' é g a r d des maladies , je ne r é p é t e r a i po in t l e s vaines e t fausses 
déclamations que font contre la Médecine l a p lupa r t des gens en s a n t é , 
mais je demanderai s ' i l y a quelque observat ion so l ide de l aque l l e on 
puisse conclure que dans l e s Pays, où cet a r t e s t le p lus nég l igé , l a 
vie moyenne de l'homme s o i t p lus courte que dans ceux où i l e s t 
c u l t i v é avec le p lus de so in" . 
J . J . Rousseau )1755) i n : Discours sur l ' o r i g i n e e t l e s fondemens de 
l ' i n é g a l i t é parmi les hommes, M.M. Rey, Amsterdam. 
F rans Th.M. Huysmans Nijmegen, 19 november 1982 


